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                    Introduction 
  
Medicinal chemistry is a science whose roots lie in all branches of chemistry and biology. It 
explains design and production of compounds that can be used for     prevention, treatment or 
cure of human or animal diseases. It is concerned with the invention, discovery, design, 
identification and preparation of biologically active compounds, the study of their mode of 
action at the molecular level and construction of structure activity relationship (SAR). The 
primary objective of medicinal chemistry is the design and discovery of new moieties that are 
suitable for use as drugs. 
Medicinal chemistry is the application of chemical research techniques to the synthesis of 
pharmaceuticals. During the early stages of medicinal chemistry development, scientists were 
primarily concerned with the isolation of medicinal agents found in plants. Today, scientists 
in this field are also equally concerned with the creation of new synthetic drug compounds. 
Medicinal chemistry received from the discovery made toward the end of nineteenth century 
by Paul Ehrlich (1854-1915), father of modern chemotheraphy, that certain compounds 
exhibited selective toxicity against particular infectious agents. On the other hand, during the 
same period, Emil Fisher’s lock-and-key theory provided a rational explanation for the 
mechanism action of drugs. Further research work by Ehrlich and his successors resulted in 
the discovery of many new chemotherapeutical agents, outstanding among which are the 
antibiotics and the sulphonamides. Medicinal chemistry is almost always geared toward drug 
discovery and development. [1] 
1.1 Drug Discovery[2,3,4,]  
 As the drug discovery process proceeds, the focus narrows as scientists develop specific 
chemicals and study their effects on identified disease targets. This requires sophisticated 
chemistry and testing on animal models of disease. 
1. INTRODUCTION 
 Fig.1 The Stages of Drug Discovery and Development 
 The steps commonly employed in the rational drug design are as follows: 
1.1.1 Target identification                   
Once they have enough understanding of the underlying cause of a disease, pharmaceutical 
researchers select a “target” for a potential new medicine. A target is generally a single 
molecule, such as a gene or protein, which is involved in a particular disease. Even at this 
early stage in drug discovery it is critical that researchers pick a target that is “drugable,” i.e., 
one that can potentially interact with and be affected by a drug molecule. 
1.1.2 Target validation 
After choosing a potential target, scientists must show that it actually is involved in the 
disease and can be acted upon by a drug. Target validation is crucial to help scientists avoid 
research paths that look promising, but ultimately lead to dead ends. Researchers demonstrate 
that a particular target is relevant to the disease being studied through complicated 
experiments in both living cells and in animal models of disease. 
 
 
 
 
1.1.3 Lead compound identification 
Armed with their understanding of the disease, scientists are ready to begin looking for a 
drug. They search for a molecule, or “lead compound,” that may act on their target to alter the 
disease course. If successful over long odds and years of testing, the lead compound can 
ultimately become a new medicine. 
There are a few ways to find a lead compound: 
• Denova: 
Medicinal chemistry scientists can also create molecules from scratch. They can use 
sophisticated computer modelling to predict what type of molecule may work. 
• High-throughput Screening:  
 This process is the most common way that leads are usually found. Advances in robotics and 
computational power allow researchers to test hundreds of thousands of compounds against 
the target to identify any that might be promising. Based on the results, several lead 
compounds are usually selected for further study. 
• Structure based drug design: 
Three dimensional structures of compounds from virtual or physically existing        libraries 
are docked into binding sites of target proteins with known or predicted structure. 
1.1.4 Lead Optimization 
Molecules are chemically modified and subsequently characterized in order to obtain 
compounds with suitable properties to become a drug.  Leads are characterized with respect 
to pharmacodynamic properties such as efficacy and potency in vitro and in vivo, 
physiochemical properties, pharmacokinetic properties, and toxicological aspects. 
1.1.5 Drug Development  
Finally, when Drug discovery occurs when a new compound is developed that addresses a 
specific disease target. After scientists identify a potentially viable drug candidate in the early 
drug discovery process, that compound proceeds to laboratory testing against      specific 
targets to determine its effect. Most compounds are eliminated as they proceed from the 
discovery to the human development phase. 
 
 
 
1.2 CHEMISTRY OF PHENOTHIAZINE [5] 
 
A cyclic organic compound containing all carbon atoms in ring formation is referred to as 
carbocyclic compound. If at least one atom other than carbon forms a part of the ring system 
then it is a designated as a heterocyclic compound. A heterocyclic ring may contain more 
than one heteroatom which may be similar or dissimilar and it may be saturated or 
unsaturated. Example: O, N, S, Se, Te, P 
Thiazines are heterocyclic compound containing a ring of four carbon, one nitrogen and one 
sulphur atom. Thiazines are used for dyes, tranquilizer and insecticide. Many compounds of 
1, 4 thiazine are known, most of them derivatives of phenothiazine. (C12H9NS) 
Phenothiazine   is a benzo derivative of thiazine compounds that are tricyclic fused ring with 
nitrogen and sulphur being the heteroatoms. The phenothiazine nucleus contains a nitrogen 
that should be considered neutral. Two aromatic ring attached to a  nitrogen, each 
withdrawing electrons reduce the basic property significantly. In most cases this nitrogen will 
not form a salt with acid. 
 
Phenothiazine 
All phenothiazines are readily oxidised, particularly in presence of the sunlight  and moisture 
and    relatively inexpensive, widely available, well tolerated and nontoxic compounds. 
Phenothiazines are electron donar compounds with low oxidation potential and they can form 
easily radical cations. It is found as the redox active unit in donar acceptor systems but also in 
ligands used for functionalizing different surfaces. 
 
 
 
 
1.2.1 MECHANISM 
Craig et al[6] have proposed the following mechanism for the oxidation of phenothiazine. 
Abstraction of an electron occurs in the first step to give the semi oxidized or semiquinone 
form (2). Loss of a proton by (2) gives the uncharged free radical (3), Loss of a second 
electron from (3) gives a stable end product (4). 
 
 
 
1.2.2 SYNTHETIC METHODS OF PHENOTHIAZINES 
¾ Vilsmeier - Haack formylation 
¾ Microwave assisted cyclo addition 
¾ Polymerization 
¾ Duff formylation 
¾ Alkylation 
¾ Smiles rearrangement 
 
 
 
 
 
Table 1. Phenothiazines as medicinal agents 
 
NAME 
 
USE 
 
STRUCTURE 
 
IUPAC NAME 
 
 
 
Dixyrazine 
 
 
Neuroleptic, 
anxiolytic 
 
 
2-{2-[4-(2-methyl-
3-phenothiazin-10yl 
propel)piperazin-1-
yl]ethoxy} ethanol 
 
 
Dimetotiazine 
 
Serotonin 
antagonist, 
migraine 
 
10-(2-
dimethylamino 
propel)-N,N-
dimethyl 
phenothiazine-2-
sulphonamide 
 
 
Etymemazine 
 
 
Anticholinergic, 
antihistamine 
 
3-(2-ethyl 
phenothiazin-10yl)-
N,N,2-trimethyl 
propan-1-amine 
 
Almemazine 
 
Antipruretic, 
eczema, 
motion sickness 
 
N,N,2-trimethyl-3-
phenothiazin-10-yl-
propane-1-amine 
 
 
 
 
Dimethoxanate 
 
 
 
 
Used in cough 
suppressant  
 
2-(2-dimethylamino 
ethoxy)ethyl 
phenothiazine -10-
carboxylate 
 
 
 
 
Ethopropazine 
 
Antiparkinsonism, 
antiadrenergic 
 
N,N-dimethyl-1-
(10H-phenothiazine-
10-yl)propan-2-
amine 
 
 
Carphenazine 
 
 
Chronic 
schizopherenia 
 
1-(10-{3-[4-(2-
hydroxy 
ethyl)piperazin-1-
ylpropyl}-10H-
phenothiazin-2-
yl)propane-1-one 
 
Dacemacine 
 
Histamine 
antagonisit (H1 
suptype), 
antitussives 
 
2-dimethylamino-1-
phenothiazine-10-
ylethanone 
 
 
 
Perazine 
 
 
Dopamine 
antagonist 
 
10-[3-(4-
methylpiperazin-1-
yl)propel]-10H-
phenothiazine 
 
 
 
Thiazinam 
 
 
 
Antihistamine 
 
N,N,N-trimethyl-1-
(10H-phenothiazin-
10-yl)propane-2-
aminium 
 
 
 
 
Fenoverine 
 
 
 
 
Antispasmodic 
 
2-{4-
[benzo(1,3)dioxol-
5-
ylmethyl]piperazin-
1-yl}-1-(10H-
phenothiazin-10-
yl)ethanone 
` 
 
 
Pipamazine 
 
Used in 
hepatotoxicity, 
morning sickness, 
and postoperative 
analgesia 
 
1-[3-(2-chloro-10H-
phenothiazin-10-
yl)propyl]piperidine
-4-carboxamide 
 
1.3 CHEMISTRY OF AZETIDINONES [7, 8] 
2-Azetidinone is a ß-lactam cyclic amide with four atoms in a ring. The ring ultimately 
proved to be the main component of the pharmacophore. So the term possesses medicinal as 
well as chemical significance. Cycloaddition of monochloro acetyl chloride with imines 
(Schiff base) result in formation of 2-azetidinone (ß-lactam).   
 
2-Azetidinone 
Traditionally ß-lactam is a part of structure of broad spectrum antibiotic class of drugs  
penicillin’s and cephalosporins. The ring ultimately is proven to be a generic descriptor for 
penicillin family. These molecules operate by forming a covalent adducts with membrane 
bound bacterial transpeptidases which are also known as penicillin binding proteins(PBPs), 
involved in the biosynthesis of cell walls. Azetidinone  has been recognized as a useful 
building block for the synthesis of a large number of organic molecules by exploiting the 
strain energy associated with it. 
1.3.1 MECHANISM 
Synthesis of β-lactam of the addition of C - N and C = O component to form a ring 
substituted acetyl chloride with electron withdrawing substituents and atleast one hydrogen at 
α-carbon add to imines in the presence of amine bases. The mechanism take place by non 
concerted cycloaddition reaction as depicted in following reaction. 
 
 
1.3.2 SYNTHETIC METHODS OF AZETIDINONES 
¾ Ketene - imine Cycloaddition 
¾ Wasserman Cyclization 
¾ Staudinger Ketene - imine Cyclization 
¾ Free Radical Cyclization 
¾ Acid Chloride Addition Reaction 
¾ Synthesis of beta - Lactams from Imidates 
¾ Microwave irradiation 
Table 2. Azetidinones as medicinal agents 
 
NAME 
 
USE 
 
STRUCTURE 
 
IUPAC NAME 
 
 
 
 
Azlocilin 
 
 
 
Acylampicill
in antibiotic 
 
(2S,5R,6R)-3,-dimethyl-7-oxo-
6{[(2R)-2-{[(2-
oxoimidazolidin-1-
yl)carbonyl]amino}-2-
phenylacetylamino}-4-thia-1-
azabicyclo[3.2.0]heptanes-2-
carboxyllic acid 
 
 
Carfecillin 
 
 
 
It is used as a 
prodrug 
(2S,5R,6R)-3,3-dimethyl-7-
oxo-6-[(3-oxo-3-(phenoxy)-2-
phenylpropanoyl]amino]-4-
thia-1-
azabicyclo[3.2.0]heptanes-2-
carboxyllic acid 
 
 
 
Ciclacillin 
 
 
Amino 
penicillin 
antibiotic 
(2S,5R,6R)-6-{[(1-
aminocyclohexyl)carbonyl]ami
no}-3,3-dimethyl-7-oxo-4-thia-
1-azabicyclo[3.2.0]heptanes-2-
carboxyllic acid 
 
 
 
Flucloxacillin 
 
Narrow 
spectrum 
penicillin 
antibiotic 
 
(2S,5R,6R)-6-({(3-(2-chloro-6-
fluorophenyl)-5-
methylisoxazole-4-
yl)carbonyl}amino)-3,3-
dimethyl-7-oxo-4-thia-1-
azabicyclo(3.2.0)heptanes-2-
carboxyllic acid 
 
 
 
Melocillin 
 
 
Broad 
spectrum 
penicillin 
antibiotic 
(2S,5S,6R)-3,3-dimethyl-6-
{[(2R)-2-[(3-methylsulphonyl-
2-oxo-imidazolidin-1-
yl)carbonyl)amino]-2-
phenylacetyl]amino]-7-oxo-4-
thia-1-
azabicyclo(3.2.0)heptanes-2-
carboxyllic acid 
 
 
 
 
Piperacillin 
 
 
Used in 
empirical 
theraphy of 
febrile 
neutropenia 
 
(2S,5R,6R)-6-{[(2R)-2-[(4-
ethyl-2,3-dioxo-piperazine-1-
carbonyl)amino]-2-phenyl-
acetyl)amino}-3,3-dimethyl-7-
oxa-4-thia-1-
azabicyclo[3.2.0]heptanes-2-
carboxyllic acid 
 
 
Ticarcillin 
 
used in plant 
molecular 
biology 
 
(2S,5R.6R)-6-{[(2S)-2-
carboxy-2-(3-
thienyl)acetyl]amino}-3,3-
dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptanes-2-
carboxyllic acid 
 
 
 
Pivmecillinam 
Used in 
empirical 
treatment of 
acute cystitis, 
and 
paratyphoid 
fever 
2,2-
dimethylpropanoyloxymethyl 
(2S,5R,6R)-6-[(azapen-1-
ylmethylene)amino]-3,3-
dimethyl-7-oxo-4-thia-1-
azabicylo(3.2.0)heptanes-2-
carboxyllic acid 
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                        Literature 
Review 
 
  
2.1 PHENOTHIAZINES AS PROMISING MEDICINAL AGENTS                         
2.1.1 Phenothiazines as anticancer agents 
1.Nagy et al[9] synthesized at a series of new tetrazolyldienyl phenothiazines derivatives 
showed in vitro anticancer activity against reversal of MDR of tumor cells. 2-Chloro-
10{(1E,3Z)-4-[2-(4-methoxyphenyl)-2H-tetrazol-5-yl]buta-1,3-dien-1-yl10Hphenothiazine 
was subjected to investigations and its reversal of MDR was studied in human MDR1 gene 
transfected mouse lymphoma cells by measuring increased the rhodamine accumulation by 
2.5 fold in our in vitro flow cytometric studies. 
 
                                                         R= Cl,  X=OCH3 
 2. Zieba et al[10]  reported  antiproliferative activity in vitro of the compounds  alkyl-12(H)-
quino[3,4-b] [1,4] benzothiazinium salts was assessed using two cancer cell lines (Hct116 
and LLC) and doxorubicin as a reference (2.2-19.6 mg/ml concentration range).                          
 
 
 
 
 
 
2.LITERATURE   REVIEW 
3. Tandon et al[11] reported a series of 2-chloro-3arylsulfanyl[1,4]naphthoquinones , 2,3-bis-
arylsulfanyl-[1,4]naphthoquinones  and 12H-benzo[b]phenothiazine-6,11-diones and their 
analogues were  evaluated for their anti proliferative activity against human cervical cancer 
(HeLa) cells. Compound 3-Methoxy-6H-benzo[b]phenothiazine-6,11(12H )- dione  were 
found to possess most potent anti proliferative and cell killing ability and antifungal activity. 
 
R=OCH3 
 
4. Bisi et al[12] demonstrated a series of phenothiazine derivatives bearing a   rigid but-2-ynyl 
amino side chain were synthesized and tested to evaluate the two haematological tumour cell 
lines, the HL60 and the CCRF/CEM, and their MDR variants HL60R and CEM/ VBL300. 
The compound  2-Chloro-10-[4-(4-phenylpiperazin-1-yl)but-2-ynyl]- 10H-phenothiazine was 
shown to increase doxorubicin retention in multidrug resistant cells, suggesting a direct 
interaction with P-glycoprotein and induce antiproliferative effects on resistant cell lines and 
to interfere with the G1 phase cell cycle.  
 
 
5.Sovilj et al[13] reported the new ruthenium(II) complexes with N alkyl phenothiazines tested 
in vitro cytotoxicity assay aganist four human carcinoma cell lines MCF7, MDA-MB-453 
(breast carcinoma), SW-480 (colon adenocarcinoma) and IM9 (myeloma multiple cells). 
Complex 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-trifluoromethyl phenothiazine 
dihydrochloride is the most sensitive against human breast cancer cell line (MDA-MB-453) 
and human colon adenocarcinoma cell line (SW-480) than other two in low concentration and 
induced almost total cell death with IC 50 value in the range of (15-25 mM). 
 
                                
6. Pluta et al[14] synthesized azaphenothiazines: tricyclic 10-substituted dipyrido thiazines , 
pentacyclic-6-substituted-diquinothiazines and hexacyclic-diquino thiazinium salt  was tested 
on 55–60 in vitro cell lines. The cell lines included nine types of cancer: leukaemia, non-
small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, 
prostate cancer and breast cancer. The most cytotoxic compound was the half-mustard 
derivative. The GI50 value of this compound was 40 ng/ml. 
 
 
 
7. Andreanil et al [15] reported the synthesis of   phenothiazine derivatives  such as  the 
substituent at position 2 is a trifluoromethyl group, of phenothiazine  most cytotoxic active 
compound  with the value of the IC 50 1 µg/ml.       
 
X=S, R=CF3, Z=CH, R1=OCH3, R11=OCH3 
 
 8.Motohashi et al[16] demonstrated the synthesis and biological activity of  several    N-acyl 
phenothiazines showed higher cytotoxic activity against human leukemic      and squamous 
carcinoma cell lines than phenothiazine, the parent compound. 10-(3 aminopropyl)-2-chloro-
10H-phenothiazine maleate, Chlorpromazine hydrochloride showed the greatest cytotoxic 
activity (CC50< 0.031 mM). 
                                              
                          10-(3 Aminopropyl)-2-chloro-                  Chlorpromazine HCL 
                            10H-phenothiazine  maleate                                                             
                                                                                                           
9. Gupta et al[17] reported Synthetic and spectral investigation of fluorinated phenothiazines 
and 4H-l ,4-benzothiazines as potent anticancer agents. 
                                                                                               
                      Fluorinated phenothiazine                        4H-1,4-benzothiazine 
 
2.1.2 Phenothiazines as antitubercular agents 
1. Shah et al [18] synthesized  2-heterocycle-substituted phenothiazines having a pyrazolo [3,4-
d] pyrimidinenucleus  by using the Biginelli multi-component cyclocondensation reaction 
and evaluated antitubercular activity against Mycobacterium tuberculosis H37 Rv by  broth 
dilution method, the MIC values in the range of > 6.25. 
 
 
2. Madrid et al[19] reported phenothiazines with reduced binding to dopamine and serotonin 
receptors examined as antitubercular agents against Mycobacterium tuberculosis H37Rv by 
microalamar blue assay.  The following compounds were proven to be the most active, with 
MIC values ranging from compounds 2 to 4 µg/ml. 
 
 Compound 1 R=2-Ph 
Compound2 R=3-Ph 
 
 
 
 
3. Mitchell et al[20] synthesized quaternized promazine and promethazine derivatives 
examined as antitubercular agents against both actively growing and non replicating 
Mycobacterium tuberculosis H37Rv by Microalamar blue assay. Impressively, several 
compounds inhibited non-replicating M. tuberculosis at concentrations equal to or double 
their MICs against the actively growing strain. N-benzyl substitution in quaternized 
promazine and promethazine is a requirement for significant antitubercular activity. 
 
                                                   
 2.1.3 Phenothiazines as antimicrobial agents 
 
1. Gautam et al[21] synthesized a series of  fluorinated 10H-phenothiazines by Smiles 
rearrangement were screened in vitro for their antibacterial and antifungal activities using 
broth microdilution method. Three compounds were found to be the most potent compounds 
against all the tested strains. 
               
                               
 
2. Wainwright et al[22] reported synthesis and biological testing of a new class of 
phenothiazinium derivatives, having either one or two tetrahydropyridine rings fused to the 
phenothiazinium chromophore. The derivatives exhibited extended absorption wavelengths, 
increased amphiphilic character and much greater photo antimicrobial efficacies compared to 
methylene blue. The high activities of this class of photosensitiser recommend its use in 
infection control, both locally and in blood product decontamination. 
                                     
                          
                     Tetracyclic derivatives                                           Pentacyclic derivatives 
 
3. Wang et al[23] synthesized a series of conjugates of metal chelators and efflux transporter 
substrates showed in vitro antibacterial activity against two gram positive and gram negative 
strains. Two compounds were found to be more potent antibacterial activity with an MIC 
value of 7.8 µg/ml against Gram positive Bacillus subtilis. 
 
 
 
 
4. Tandon et al[24] synthesized a series biological evaluation of novel nitrogen and sulphur 
containing hetero-1,4-naphthoquinones tested for in vitro antifungal and antibacterial activity. 
Most of the compounds showed moderate to strong antibacterial activity and  compound 2-
Chloro-3-(4-hydroxyphenylamino)naphthalene-1,4-dione better antifungal activity than 
standard drug Fluconazole against Sporothrix schenckii Candida albicans, Cryptococcus 
neoformans  and Trichophyton mentagraphytes (MIC=0.78 µg/ml). 
 
2-chloro-3-(4-hydroxyphenylamino)naphthalene-1,4-dione 
 
5. Ojha et al[25] reported a series of some new phenothiazine derivatives were synthesized and 
evaluated for in vitro antibacterial activity against gram positive and gram negative bacterial 
strains.  Preliminary results indicated that most of the compounds demonstrated very good 
antibacterial activity, comparable to standard drug. 
 
6. Kostecka et al[26] synthesized a series of benzo[a]phenothiazine derivatives and evaluated 
in their  in vitro antifungal activity against pathogenic strains. Preliminary results indicated 
that most of the compounds demonstrated very good antifungal activity, comparable to 
standard drugs. The most effective compounds have exhibited activity at MIC of 6.25 mg/ml. 
 
 
 
7.  Kumar et al[27] reported  Benzimidazolyl-Phenothiazine Derivatives  showed in vitro 
antibacterial activity against pathogenic strains by disc diffusion method . Three compounds   
were found to be more potent antibacterial activity against E.Coli, B.subtilis, S.aureus. 
 
                                                           Compound1 R=P-Cl 
                                                           Compound2 R= M-OH 
                                                           Compound3 R=M-NO2 
 
8. Raval et al[28] demonstrated a variety of N (2-methyl-7-aryl-8-cyano-[1,2,4] triazolo [1,5-a] 
pyridin-5-yl) phenothiazines were synthesized by using chalcones of N – acetylphenothiazine 
showed antimicrobial activity by streak plate and  cup plate method. some of these 
compounds have shown significant antibacterial and antifungal activities. 
 
 
9. Talesara et al[29] reported phthalimido or succinimido-[2-aryl-4-oxo-3-[{2-oxo-2-
(phenothiazin-10-yl)ethyl}amino]-1,3-thiazolidin-5-yl]ethanoate evaluated in vitro antifungal 
and antibacterial activity against pathogenic strains. All the compounds have shown 
significant inhibition of bacterial and fungal growth. 
 
 
   
10. Radadiya et al[30] synthesized  a series of 10N-{[Aryl}-amino]-methyl}-3-methoxy-
10,10a-dihydro-4a-H-phenothiazine-9-carboxyllic acid in presence of Mannich reaction. The 
biological activity of these compounds have been determined against various gram positive, 
gram negative bacteria and fungi by cup-plate method, which revealed that all tested 
compounds of this investigation were moderate to highly active against all the tested 
pathogenic bacteria and fungi. 
 
 
11. Loiseau et al[31] evaluated  Phenothiazines and related polycyclics as new lead structures  
determined  for in vitro  trypanocidal  activity against Trypanosoma brucei and antifilarial 
activity against Molinema dessetae infective larvae. Lead compound  naphtha (2’3’: 4,5) 
thiazoio (3,2-a) benzimidazole -7,12-dione was the most antifilarial  with IC50, of 8 µM. A 
slight effect was observed against the trypanosomes maintained and minimum inhibitory 
concentrations of active compounds were 50 µM. 
 
 
12. Dongre et al[32] synthesized a series of 2-substituted N-acylphenothiazines were 
synthesized by using imides, N-carboxymethyl imides and the structures of these newly 
synthesized compounds were confirmed by spectral and elemental analyses. All new 
compounds were tested for their antibacterial and antifungal activities against pathogenic 
strains. The preliminary screening results indicated that most of the compounds demonstrated 
moderate to very good antibacterial and antifungal activities compared to the first-line drugs. 
                                                                   
 
13. Rathore et al[33] reported 7-Chloro-5-trifluoromethyl-7-fluoro-7-trifluoromethyl-4H-1,4-
benzothiazines have been synthesized by 2-amino-5-fluoro/5-trifluoromethyl/5-chloro-3-
trifluoromethyl benzenethiols condensed with b-diketone/b-ketoesters in the presence of 
DMSO involving oxidative cyclization and evaluated biological  activity of antibacterial and 
antifungal against their pathogenic strains. The following were the most potent compounds 
reported.  
 
 
 
 
 
  
 
                                                                      Compound1 R1= H, R2=F, R3=CH3, 
                                             Compound2 R1= H, R2=F, R3=CH3, R4=C6H4C2H5(P) 
                                        Compound3 R1= H, R2=F, R3=CH3, R4=C6H4Cl(P) 
 
14. Ihara et al[34] evaluated a series of phenothiazinium chlorides were synthesized and 
evaluated for in vitro antiprotozoal activities against Plasmodium falciparum, Trypanosoma 
cruzi Trypanosoma brucei rhodesiense, and Leishmania donovani. The compound  3,7 
bis(piperidinyl)phenothiazinium chloride showed IC50 of 0.097 µmol L-1 against T. cruzi and 
3,7-bis(benzyl(methyl)amino)phenothiazinium chloride exhibited IC50 of 0.081 µmol L-1 
against L. donovani, although the cytotoxicities of these compounds against L-6 cells were 
observed at low concentration. 
 
   
3,7bis(piperidinyl)phenothiazinium chloride 
 
 
3,7bis(benzyl(methyl)amino)phenolthiazinium chloride 
 
15. Upadhyay et al[35] synthesized a series of 1-[2-(10-p-Chlorobenzyl) pheno- thiazinyl]-3-
(substituted aryl)-2-propen-1-ones evaluated antimicrobial activity by Filter Paper Disc 
method. The preliminary screening results indicated that most of the compounds 
demonstrated moderate to very good antibacterial and antifungal activities compared to 
standard chloramphenical.                                                                                                                
 2.1.4  Phenothiazines an antiviral agent 
1. Mucsi et al[36] reported  combination of some benzo[a]phenothiazines and 9-[2-hydroxy 
(ethoxy) methyl]guanine (acycloguanosine, acyclovir, ACV) and evaluated their in vitro 
antiviral activity against herps simplex virus (HSV-2). Two most effective derivatives of 5-
oxo-5H-benzo[ a]phenothiazine and  6-methyl-5-oxo-5H-benzo[a]phenothiazine were  used 
with ACV against a wild type HSV-2 strain and enhance their antiviral activity. 
                                                                       
                     5-oxo-5H-benzo[ a]phenothiazine              6-methyl-5-oxo-5H-benzo[a]phenothiazine 
2.1.5 Phenothiazines as antimalarial agent 
1. Tilley et al[37] synthesized a series of novel phenothiazine compounds showed in vitro 
antimalarial activity  that inhibit the growth of both chloroquine-sensitive and chloroquine 
resistant strains  of plasmodium falcifarum. Each phenothiazine that possess an alkyl amino 
side chain linked to the nitrogen atom showed inhibitory activity. The potent compound 2-
Chloro-10-[3-(N,N-bis(N,N-(dimethyl amino)-propyl)amino)propyl}-10H-phenothiazine 
which has a branched tribasic side chain showed good antimalarial activity as a inhibition of 
β- heamatin. 
 
 
 
 
 
 
2.1.6 Phenothiazines as anticonvulsant agents 
 
1. Scotte et al[38] reported a series of 3-Carboalkoxy-2-methyl-2,3-dihydro-1H-phenothiazin-
4[10H)-one Derivatives showed for their in vivo anticonvulsant activity. The compound  
trans-7-Bromo-lcarbo-tert-butoxy-2-methydihydro-1H-phenothiazin-4[10H)-one showed 
better anticonvulsant activity. 
 
Trans-7-Bromo-lcarbo-tert-butoxy-2-methydihydro-1H-phenothiazin-4[10H)-one 
2. Kumar et al[39] synthesized a series of 10-[7,11-(2,4 di substituted phenyl)-3-oxo-9-
aminoimino-2,4-diazaspiro[5,5] phenothiazine derivatives evaluated  in vivo  anticonvulsant 
activity against electrically (MES) and chemically (PTZ, picrotoxin and bicuculline) induced 
seizures and compared with the standard drugs phenytoin, and sodium valproate. The 
compound 10-[7,11-(3,5disubstituteddiphenyl)-3-thia-9-aminoimino-2,4-diazaspiro[5,5] 
undecane 1,5-dione]acetyl phenothiazine was found to be most potent compound of this 
series. 
 
R=4-OCH3,C6H5 
 
 
 
2.1.7 Phenothiazines as antihistaminic and anti-inflammatory agents 
1. Isobe et al[40] synthesized a series of tricyclic carboxylic acids having 6-amino-pyrimidine-
2,4(1H,3H)-dione with piperazino or homopiperazino moiety linked by propylene, and 
evaluated for their in vivo anti-histaminic activity and in mice, bioavailability in rats, and 
their anti-inflammatory activity in mice OVA-induced biphasic cutaneous reaction model. 
Among the compounds tested, dibenzoxazepine carboxylic acid  showed both histamine H1 
receptor antagonistic activity and anti-inflammatory activity. 
 
 
n=2, X1, Y1 = O, CH2, Z = bond 
 
2. Isobe et al[41]  synthesized a series of phenothiazine carboxylic acid derivatives, having 6-
amino-pyrimidine-2,4(1H,3H)-dione moiety  were  evaluated for their in vivo oral 
antihistaminic activity in mice and bioavailability in rats. Finlly  promising compounds were 
examined for their anti-inflammatory potential in mice OVA-induced biphasic cutaneous 
reaction model. Among the compounds tested, phenothiazine acetic acid compound  showed 
both histamine H1-receptor antagonistic activity and anti-inflammatory activity. 
 
 
3.  Rao et al[42]  reported a number of substituted phenothiazines were synthesized and 
screened for their in vitro enzyme inhibitory  activity against the regulatory enzymes 
involved in inflammatory diseases. The compounds  2,10-dihydro-1H-phenothiazine  and 2-
aryl-10H-phenothiazine derivatives  exhibited promising in vitro enzyme inhibitory activity 
and further structural variation of these compounds could result in designing a potent lead 
molecules in the therapy of many inflammatory diseases. 
 
 
4. Rajasekaran et al[43] synthesized  a series of 5[b-(phenothiazinyl-10-yl)ethyl]- 1-(acyl)-
1,2,3,4-tetrazoles  were in vitro screened for analgesic activity  tested both by acetic acid 
induced writhing method and hot plate method and anti-inflammatory activity tested by 
carrageen in induced paw oedema method. Out of the 12 compounds synthesized, compound  
5[b-(phenothiazinyl-10-yl)ethyl]- 1-(benzoyl)-1,2,3,4-tetrazole, compound  5[b 
(phenothiazinyl-10-yl)ethyl]-1-(p-tolyl)-1,2,3,4-tetrazole showed promising analgesic activity 
and compound 5[b-(phenothiazinyl-10-yl)ethyl]-1-(p-chlorobenzoyl)-1,2,3,4-tetrazole and 
compound  5[b-(phenothiazinyl-10- yl)ethyl]-1-(p-nitrobenzoyl)-1,2,3,4-tetrazole showed 
promising anti-inflammatory activity. 
 
 
                                                                 
                                                                          
                                                          
2.1.8 Phenothiazines as antioxidant agents 
 
1. Kumar et al[44] synthesized quinolinobenzothiazinones have been evaluated for their 
antioxidant (LPO & GSH) and radical scavenging activities by DPPH and ABTS assays. The 
synthesized compounds have also shown antioxidant activity as measured by estimating 
reduced glutathione (GSH) and lipid peroxidation (LPO) in liver of Swiss albino mice. The 
following compounds possessed excellent antioxidant activity. 
 
Compound1: R1=OCH3, R2=H, R3=OCH3, R4 
Compound2: R1=H, R2=Br, R3=OCH3, R4=H 
Compound3: R1=CF3, R2=H, R3=H, R4=CH3 
 
2. Dixita et al[45] reported  10H-phenothiazines are prepared by Smiles rearrangement. These 
prepared phenothiazines are used as base to prepare ribofuranosides by treatment with β 
Dribofuranosyl- 1-acetate-2,3,5-tribenzoate and evaluated in their in vitro antioxidant activity 
and antimicrobial activity. Some compounds were found to be  good  antioxidant activity and 
all the compounds  exhibited  moderately active against various bacteria, such as 
Staphylococcus aureus and Pseudomonas flueroscense and fungi Aspergillus niger, 
Aspergillus flavus. 
 
 
2.1.9 Phenothiazines as antialzheimer agent 
 
1. Conde  et al[46] reported  that N-acyl amino phenothiazines showm antialzheimer’s activity 
in brain of alzehimer’s disease model mice, mechanism involved was proposed as  inhibition 
of  butyrylcholinesterase (BuChE), protected neurons against damage caused by both 
exogenous and mitochondrial free radicals, showed low toxicity, and could penetrate into the 
CNS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 AZETIDINONES AS PROMISING MEDICINAL AGENTS 
 
2.2.1 Azetidinones  as anticancer agents  
 
1. Noolvi et al[47] synthesized  a series of 1-methyl-N-[(substituted phenylmethy lidene)-1H-
benzimidazol-2-amines and evaluated in vitro cytotoxicity and antibacterial activity aganist 
MCF-7 cell line by MTT assay. All compounds  exhibited moderately antibacterial activity  
and 3-Chloro-4-(2,5-dimethoxyphenyl)-1-(1-methyl-1Hbenzimidazol- 2-yl) azetidin-2-one 
shown good cytotoxicity activity  with IC50 value in the range of 6.0 µM. 
 
3-Chloro-4-(2,5-dimethoxyphenyl)-1-(1-methyl-1Hbenzimidazol- 2-yl) azetidin-2-one 
 
2. Meegan et al[48] investigated synthesis and study of the structure activity relationships of a 
series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-
azetidinone (β-lactam) ring system  and evaluated in their antiproliferative activity and 
tubulin targeting effects against MCF-7 and MDA-MB-231 human breast carcinoma cell 
lines. Two compounds display antiproliferative activity and antimitotic effects through an 
inhibition of tubulin polymerisation and subsequent G2/M arrest of the cell cycle in human 
MDA-MB-231 breast cancer cells, with similar activity to that of CA-4. 
 
Compound1: R1=H, R2=H 
      Compound 2: R1=CH3, R2=H 
 
 
 
3. Lotufo et al[49] 2-Azetidinones and 2H-azirines were assayed for antibacterial and cytotoxic 
activities. None of them showed antibacterial activity on the tested strains, but both 2H-
azirine-2-azetidinones showed cytotoxicity against four tumour cell lines (HL-60, leukaemia, 
HCT-8, colon cancer, MDA-MB-435, melanoma and SF-295, CNS). The IC50 values  ranged 
from 1.1 to 10.5 µM. 
 
 
1-(4-chloride)-3,3-diphenyl-4-(3-phenyl-2H-azirinyl)-2-azetidinone 
 
4. Meegan et al[50] synthesized a series azetidin-2-ones  derivatives  and evaluated for 
antiproliferative, cytotoxic and tubulin-binding activity. Heterocyclic derivatives, 3-(2-
thienyl) analogue 28 and 3-(3-thienyl) analogue  displayed the highest potency in human 
MCF-7 breast cancer cells with IC50 values of 7 nM and 10 nM,. No significant toxicity was 
observed in normal murine breast epithelial cells. 3-naphthyl derivative  and 3-benzothienyl 
derivative , resulted in relatively lower antiproliferative activity in the micromolar range. 
Tubulin-binding studies of 3-(thienyl) β-lactam   confirmed that the molecular target  of this 
series of compounds is tubulin.  
                                                                     
                       Compound1:R=2-thienyl                                   Compound 3:R1=2-naphthyl 
                       Compound2:R=3-thienyl                                   Compound4:R1=benzothienyl 
 
 
5. Muniz et al[51] reported in vitro cytotoxictity assay several enantio pure (3S,4S)- and 
(3R,4R)-1,3,4,4-tetrasubstituted β-lactams derived from amino acids against HT29 cell lines. 
The compound (3S,4S)-4-benzyl-1-p-methoxybenzyl-3- methyl-4-methoxycarbonyl 
derivative showed significant activity compared to standard  drug Doxorubicin. 
  
6. Meegan et al[52]  reported that structure-activity relationships and  synthesis of azetidinone 
series of compounds was achieved utilizing the Staudinger and Reformatsky reactions. The 
antiproliferative activity was assessed in MCF-7 cells, where the 4-(4-ethoxy)phenyl 
substituted compound displayed the most potent activity with an IC50 value of 0.22 µM and 
arrest of MCF-7 cells in the G2/M phase of the cell cycle and induction of apoptosis. 
 
 
7.Kumar et al[53] 3-Azido-3-amino and 3-(1,2,3-triazol-1-yl)-β-lactams were synthesized and 
evaluated for their antiplasmodial activity against four strains of Plasmodium falciparum and 
KB cells for their cytotoxicity profiles. The presence of a cyclohexyl substituent at N-1 and a 
phenyl group on the triazole ring markedly improved the activity profiles of triazole-tethered 
β-lactam exhibiting IC50 values of 6.25 µM against 3D7, K1 and W2 strains respectively. 
 
 
 
 
 
 
2.2.2 Azetidinones as antitubercular agents 
 
1. Omprakash et al[54] synthesized a series of azetidinones and 4-thiozolidinones of 4,4’ 
sulphonyl aniline were screened for their in vitro antifungal ,antibacterial and antitubercular 
activity against mycobacterium tuberculosis H37RV  by Lowenstain-Jension medium 
method. All the synthesized compounds exhibited moderate to potent activities of antifungal, 
antibacterial and antitubercular activity.  
 
 
2. Chikalia et al[55] reported pyrimidine based azetidinones  derivatives  evaluated in their 
antitubercular activity against Mycobacterium tuberculosis H37RV. The β-lactam ring 
connected to ureido linkage showed moderate to excellent antitubercular activity. 
 
 
 
3. Basawaraj et al[56] synthesized a series of azetidinone and thiazolidinones derivatives from 
5-chloro-3-methyl benzofuran and evaluated their antitconvulsion and antitubercular activity 
against Mycobacterium tuberculosis H37RV strain  by broth dilution method.  Results of the 
antitubercular screening showed two compounds with good antitubercular activity , when 
compared with streptomycin  and None of the tested compounds abolished pentylene tetrazol 
induced convulsions in test animals. 
 
 4. Ilango et al[57]  reported the synthesis of novel trihydroxy benzamido azetidin-2-one 
derivatives and evaluated in vitro antibacterial,  antitubercular activity aganist 
Mycobacterium tuberculosis H37RV strain by microplate alamarblue assay. Some 
compounds exhibited very good antibacterial and antitubercular activities. 
 
 
 
5. Dubey et al58] carried out the synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of 
benzotriazole and screening for their in vitro antitubercular activity against Mycobacterium 
tuberculosis H37RV strain by agar micro dilution method. Some compounds exhibited 
excellent antitubercular activity. 
 
 
6. Dighe et al[59] investigated synthesis and evaluation of isatinyl thiazole derivatives as anti-
Mycobacterium tuberculosis agents by broth micro dilution method and MIC value in the 
range of 6.25 µg/ml.   
 
 
7. Sharma[60] et al reported 1-(nicotinylamino)-2 substituted azetidin 4-ones have been 
synthesized. They have exhibited significant activity against the bacteria and fungi and also 
anti-tubercular activity. 
  
2.2.3 Azetidinones  as antimicrobial agents 
 
1. Sahoo et al[61] synthesized novel azetidinone derivatives showed in vitro antibacterial and 
antifungal activity against pathogenic strains. The preliminary screening results indicated that 
most of the compounds demonstrated moderate to very good antibacterial and antifungal 
activities.   
 
 
2. Zarei et al[62] reported a series of 3-thiolated β-lactams were synthesized by [2+2] ketene 
imine cycloaddition reaction from S-substituted mercaptoacetic acids and Schiff bases. All 
the compounds were characterized by spectral data and elemental analyses and were 
evaluated for their in vitro antibacterial and antifungal activities against pathogenic strains 
including Staphylococcus aureus (Methicillin resistant strain). The preliminary screening 
results indicated that some of these compounds demonstrated moderate to very good 
antibacterial and antifungal activities. 
                                       
                      3-(methylsulfonyl) b-lactams               (methylsulfinyl) b-lactams 
 
  
 
 
 
 
3. Halve et al[63]  synthesized  a series of 3-chloro-4-(3-methoxy-4 acetyloxyphenyl)-1-[3-
oxo-3-(phenylamino)propanamido] azetidin-2-ones  and 3-chloro-4-[2-hydroxy-5-(nitro 
substituted phenylazo)phenyl]-1-phenylazetidin-2-ones were established on the basis of 
elemental analysis and spectroscopic data. The antimicrobial activity of the synthesized 
compounds was screened against several microbes. Several of these molecules showed potent 
antimicrobial activity against Bacillus anthracis, Staphyococcus aureus and Candida 
albicans and significant structure–activity relationship (SAR) trends. 
 
3-chloro-4-(3-methoxy-4 acetyloxyphenyl)-1-[3-oxo-3-(phenylamino)propanamido] 
                                                                                                           azetidin-2-ones 
 
3-chloro-4-[2-hydroxy-5-(nitro substituted phenylazo)phenyl]-1-phenyl 
                                                                                                                      azetidin-2-ones 
 
4. James et al[64] reported a series of novel Azetidinone derivatives have been synthesized 
from the intermediate Schiff bases. Cyclocondensation of schiff’s bases with acetylchloride 
resulted in the formation of azetidinone derivatives. The compounds, characterized on the 
basis of satisfactory spectral data (IR, NMR and  Mass spectroscopy)  have shown moderate 
to good antimicrobial activity against some bacteria and fungi. 
 
 
 
 
5. Meshram et al[65] synthesized novel N-thiazole, 3-phenyl, 4-substituted phenyl azetidin-2-
ones were screened for their in vitro antibacterial activity against four microorganisms: 
Staphylococcus aureus (Gram positive), Pseudomonas vulgaris (Gram positive), 
Pseudomonas Aeruginosa (Gram negative) and Escherichia coli (Gram negative).The 
antibacterial screening data shows three compounds are highly active against the used strains. 
                                                            
  2,3-diphenyl-4-(1,3-thiazol-2-yl)cyclobutanone                    3-(2-hydroxyphenyl)-2-phenyl 
                                                                                                 l-4-(1,3-thiazol-2- yl)cyclobutanone 
 
3-(2-furyl)-2-phenyl-4-(1,3-thiazol-2- yl)cyclobutanone 
 
6. Rokade et al[66] reported azetidinone derivatives were synthesized from β-naphthol and 
screened for their anti-bacterial and antifungal activities.   
 
7. Synthesis and herbicidal activity of different azetidinones were  reported by Gajari et al[67]. 
some of these compounds showed  good herbicidal activity. 
 
R=Alkyl, Aryl, Hetero 
                       
 
 
 
2.2.4 Azetidinones as antimalarial agents 
 
1. Kaushik et al[68] reported  a series of bicyclic N-substituted and unsubstituted β-lactams 
were synthesized and evaluated as targeted potential antimalarials. The compounds MNR4 
and MNR5 were found to have highest potency against Plasmodium falciparum in vitro. 
                                                           
                                           MNR4                                           MNR5 
 
2. Jarrahpour et al[69] demonstrated Some new mono-, bis-spiro- and dispiro-β lactams have 
been synthesized from imines derived from 9H-fluoren- 9-one and  ketene by [2+2] 
cycloaddition reaction. The in vitro antimalarial activity of these monocyclic β-lactams was 
successfully investigated against Plasmodium falciparum K14 resistant strain with excellent 
EC50 values up to 5 mM. 
 
2.2.5 Azetidinones as anticonvulsant agents 
 
1. Pawar et al[70] synthesized a series of  N-Substituted-7-hydroxy-4-methyl-2-oxoquinolines 
evaluated in vivo for their  anticonvulsant activity by MES and two compounds showed 
significant anticonvulsant activity. 
 
 
   Compound1: R=C4H3O 
Compound2: R=C6H5 
 
 
2. Soodet al[71] reported a series of 5-[(3’ chloro-4’-substituted phenyl -2’-oxo-azetidin-1’-
yl)amino] barbituric acid have been synthesized and it shows better anticonvulsant activity.   
 
2.2.6 Azetidinones as anti-inflammatory agents 
1.Synthesis of 3-[40-(p-chlorophenyl)-thiazol-20-yl]-2-[(substituted azetidinone 
/thiazolidinone)-aminomethyl]-6-bromoquinazolin-4- ones as anti-inflammatory agent were 
reported by Kumar et al[72]. 2-[(40-Oxo-30-chloro-20-{o-chlorophenyl}-azetidin- 10-
yl)aminomethyl]-3-[400-(p-chlorophenyl)thiazol-200-yl]-6-bromoquinazolin-4-one showed 
promising anti-inflammatory and analgesic  activity. 
 
 
2. Kumar et al[73] synthesized a series of Indole derivatives were screened for their  in vivo anti-
inflammatory and analgesic activity.  All the compounds exhibited  moderate to good  anti 
inflammatory and analgesic activity. 
 
3. Kumar et al[74] synthesized a series of substituted azetidinoyl and thiazolidinoyl-1,3,4-
thiadiazino (6,5-b) indoles were evaluated for their in vivo anti-inflammatory, ulcerogenic 
and analgesic activities. Compound   2-3-chloro-4-aryl-1-{5 [{[1,3,4]thiadiazino(6,5-b) 
indol-3-ylamino]methyl]-1,3,4-thiadiazol-2-yl}azetidin-2-one has shown most active anti-
inflammatory and analgesic activities with better ulcerogenic activity than phenylbutazone. 
 
4. Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives as anti-
inflammatory agent were reported by   Kumar et al [75]. All the compounds showed promising 
anti-inflammatory activity. 
 
 
2.2.7 Azetidinones as antiparkinsonism agent 
 
1. Kumar et al[76] synthesized a series of  azetidinonyl/thiazolidinonyl quinazolinone 
derivatives were screened for their antiparkinsonism activity. All   azetidinone derivative 
compounds shown mild activity compared to thiazolidinone derivatives. 
 
 
 
 
 
2.2.8 Azetidinones as antidepressant agent 
 
1. Thomas et al [77] reported synthesis and biological evaluation of Schiff’s bases and 2-
azetidinones of isonocotinyl hydrazone were screened for their antidepressant and nootropic 
activity. All synthesised Schiff’s bases and azetidinone analogues exhibited antidepressant 
and nootropic activity. The results confirmed the fact that the 2-azetidinone skeleton has 
potential as a CNS activity.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 
 
 
 
 
 
              Objectives of the 
Present study 
 
 Phenothiazine and its derivatives reported to possess antipsychotic, antiemetic, antihistamine, 
antiinflammatory, anthelmintic, antitubercular, antimicrobial, antitumour, antiparkinsonism 
and anticancer agents. A slight variation in the substitution pattern on the phenothiazine 
nucleus often resulted in a marked difference in activities and therefore phenothiazines with 
various substituents are being synthesized and tested for various activities in search of better 
medicinal agents.  
Azetidin-2-ones also reported to possess wide therapeutic activity viz. sedative, hypnotics, 
anticonvulsant,  antimicrobial, antitubercular, antidiabetic, anti-inflammatory, analgesic 
activity, anticancer and antiparkinsonism activities.  
An attempt was made to synthesize some new congeners by linking azetidinones with 
phenothiazine pharmacophore to evaluate their possible synergic activity as there were no 
reports on phenothiazine derivatives containing azetidinone moiety. β-lactam ring connected 
to ureido linkage possess  significant antitubercular  activity and tricyclic compounds 
containing NH and thio group with rigid side chain reported to possess significant 
antimicrobial, antioxidant and anticancer activity. With this background, a series novel 
phenothiazine derivatives flanked with azetidinones were synthesized and evaluated for in 
vitro  antimicrobial, antitubercular, antioxidant  and anticancer  activity. 
The objectives of the present work are to: 
• synthesize various substituted phenothiazine derivatives  
• characterize the synthesized compounds using  FT-IR, 1H-NMR and mass spectroscopy 
• carry out in vitro antimicrobial, antitubercular, antioxidant and anticancer evaluation of  
the  synthesized derivatives  
• explain the possible SAR of the synthesized derivatives. 
 
3.OBJECTIVES OF THE PRESENT STUDY 
Chapter 4 
 
 
 
 
 
 
 
Experimental Work 
 
4.EXPERIMENTAL WORK
  
SYNTHESIS OF PHENOTHIAZINE DERIVATIVES 
4.1 SCHEME 1 
4.1.1  STEP 1:  Synthesis of 2-chloro-1-(10H-phenothiazin-10-yl)ethanone  from 
phenothiazine 
 
Procedure 
Chloroacetyl chloride (0.02 mol, 1.68 ml) was added drop by drop at 0-50C to phenothiazine 
(0.01 mol, 1.99 g) in dry benzene (50 ml) and stirred for 2 h. Solution was kept at room 
temperature where the solid separated was filtered and washed with petroleum ether and 
recrystallized from chloroform.[33,40] 
4.1.2   STEP 2:   Synthesis of 4-(2-oxo-2-(10H-phenothiazin-10yl)ethyl) semicarbazide 
 
Procedure 
A mixture of 2-chloro-1-(10H-phenothiazin-10-yl) ethanone (0.01 mol, 2.75 g) and 
semicarbazide (0.04 mol, 3 g) in absolute ethanol was refluxed for 5 h. Contents were poured 
into ice cold water. The resulting solid was filtered, dried and recrystallised from 
chloroform.[30,78] 
 
 
 
4.1.3 STEP 3:  Synthesis of schiff’ base 
 
R= H, H, 4-OCH3, 4-N(CH3)2, [4-OH, 3-OCH3], 4-NO2, 2-Cl,  
4-Cl, 4-OH, 3-Cl, 3-F 
Procedure: 
Mixture of 4-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)semicarbazide (0.01 mol, 3.14 g) and 
substituted benzaldehyde (0.01 mol, 1.06 ml)  in ethanol containing acetic acid (0.5 ml) was 
refluxed for 6 h. Excess of solvent was distilled off, concentrated and cooled. The solid thus 
separated was filtered, washed and recrystallised from ethanol.[79,80] 
4.1.4 STEP4: 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-pheno thiazin-
10-yl)ethyl)urea Derivatives. 
 
R= H, H, 4-OCH3, 4-N(CH3)2, [4-OH, 3-OCH3], 4-NO2, 
2-Cl, 4-Cl, 4-OH, 3-Cl, 3-F 
 
 
 
Procedure 
Chloroacetyl chloride (0.01 mol, 1.12 ml) was added dropwise to substituted Schiff’s base 
(0.005 mol, 1.93 g) and triethylamine (0.01 mol, 1.01 ml) in 1,4 dioxane (12.5  ml) over a 
period of 30 minutes. The reaction mixture was refluxed for 5 h and filtered. The filterate is 
concentrated half its volume, then poured into crushed ice. The product obtained was filtered 
and washed  with water and recrystallised from ethanol.[81] 
4.2 SCHEME-2 
4.2.1   STEP 1:  Synthesis of 2-chloro-1-(10H-phenothiazin-10-yl)ethanone from 
phenothiazine 
 
Procedure 
Chloroacetyl chloride (0.02 mol, 1.68 ml) was added drop by drop at 0-50C to phenothiazine 
(0.01 mol, 1.99 g) in dry benzene (50 ml) and stirred for 2 h. Solution was kept at room 
temperature where the solid separated was filtered and washed with petroleum ether and 
recrystallized from chloroform.[33,40] 
4.2.2   STEP 2:  Synthesis of 4-(2-oxo-2-(10H phenothiazin 10yl)ethyl)thio semicarbazide 
 
 
 
 
Procedure: 
A mixture of 2-chloro-1-(10H-phenothiazin-10-yl)ethanone (0.01 mol, 2.75 g) and 
thiosemicarbazide (0.04  mol, 3.4 g) in absolute ethanol was refluxed for 5 h. Contents were 
poured into ice cold water. The resulting solid was filtered, dried and recrystallised from 
chloroform. 
4.2.3  STEP 3: Synthesis of schiff’ base 
 
R= H, H, 4-OCH3, 4-N(CH3)2, [4-OH, 3-OCH3], 4-NO2, 2-Cl, 
 4-Cl, 4-OH, 3-Cl, 3-F 
  Procedure: 
Mixture of 4-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiosemicarbazide (0.01 mol, 3.30 g) 
and  substituted benzaldehyde (0.01 mol, 1.06 ml)  in   ethanol (20 ml) were taken in a 
beaker. The mixture was heated on a water bath for 3 h, until a clear solution was obtained. 
The clear solution was kept overnight when respective Schiff’s base fall out which was 
filtered, washed by petroleum ether and air dried.[82] 
 
 
 
 
 
 
4.2.4 STEP4: 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-pheno thiazin-
10-yl)ethyl)thiourea derivatives 
 
 
R= H, H, 4-OCH3, 4-N(CH3)2, [4-OH, 3-OCH3], 4-NO2, 2-Cl,  
4-Cl, 4-OH, 3-Cl, 3-F 
Procedure 
Chloro acetylchloride (0.01 mol, 1.12 ml) was added drop wise to the mixture of 
triethylamine (0.01 mol, 1.01 ml in 12.5 ml of dry 1,4 dioxane) and solution of substituted 
Schiff bases  (0.005 mol, 2.01 g). The reaction mixture was stirred for 30 min and then 
refluxed for 5 h. A solid was obtained was recrystallized from a mixture of ethanol and 
water.[83] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.3.1 Melting point 
 The melting points of all the synthesized compounds were determined using capillary tubes 
with Thermonic model C-LMP-1-Campbell melting point apparatus and are uncorrected 
(Table 5). 
4.3.2 Thin layer chromatography 
The synthesized compounds were tested for their purity by performing TLC over glass plates 
coated with silica gel with suitable mobile phase system and detected by iodine vapour 
(Table 5).  
4.3.3 Infra red spectroscopy 
The structures of the synthesized compounds were elucidated by JASCO FTIR-4100 
spectrophotometer in KBr disc (Table 6).  
4.3.4 NMR spectroscopy 
 1HNMR spectral study was done using AV-III 400 Fourier Transform NMR 
spectrophotometer in TMS as standard (Table 6). 
4.3.5 Mass spectroscopy 
Mass spectra of selected compounds were determined on JOEL SX 102 -GC MATE 700 EV 
instrument employing electron impact ionization technique (Table 6). 
 
 
 
4.3 CHARACTERIZATION 
Chapter 5 
 
       
 
 
 
 
 
        Biological Screening 
 
      
 
5.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING 
Antimicrobial susceptibility testing is indicated for any organism that contributes to an 
infectious disease warranting antimicrobial chemotherapy, if its susceptibility cannot be 
reliably predicted from pre-existing antibiograms. The introduction of a variety of 
antimicrobials today makes it a necessity to perform the antimicrobial susceptibility test, the 
results of which can guide us to the selection of appropriate antimicrobial drug with 
unquestionable benefit and least problem of antimicrobial resistance (AMR). Two methods were 
used for the antimicrobial susceptibility testing.[84,85,86] 
• DISC DIFFUSION METHOD  (Zone of inhibition) 
• SERIAL DILUTION METHOD  (Minimum inhibitory concentration) 
 
5.1.1 ANTIBACTERIAL SCREENING (Disc diffusion method) 
The antibacterial activities of synthesized compounds were screened in the concentration of 1 
µg/µl in dimethyl sulphoxide (DMSO) against the listed microorganisms, obtained from 
National Collection of Industrial Microorganisms (NCIM), Pune and Microbial Type Culture 
Collection (MTCC), Chandigarh, in the Muller Hinton agar medium by disc diffusion method 
using ciprofloxacin (0.5 µg/µl) as standard. The antibacterial activity was evaluated by 
measuring zone of inhibition in mm. 
 
 
 
 
 
 
 
Table 3. List of bacterial strains used in the study 
GRAM POSITIVE GRAM NEGATIVE 
Micrococcus luteus NCIM 2169 Escherichia coli NCIM 2068 
Staphylococcus aureus NCIM 2079 Pseudomonas aeruginosa NCIM 2206 
Bacillus subtilis NCIM 2063 Salmonella Paratyphii NCIM 2075 
Staphylococcus albus NCIM 2178 Vibreo cholera MTCC 1738 
5. BIOLOGICAL SCREENING 
5.1.1.1 PREPARATION OF INOCULUMS 
Preparation of inoculums of bacteria was carried out by Muller Hinton Broth and transferred 
to test tube and kept it for sterilization in autoclave at 1200 C for 15 min. Then added culture 
of each bacteria to each tube (this step was carried out in aseptic room near laminar air flow) 
then  kept it  for   incubation in  incubator for 18-24 h at 370 C. 
5.1.1.2 PROCEDURE 
Muller Hinton agar medium  was prepared by dissolving  21 g of Muller Hinton agar in 1000 
ml of distilled water and  agar-agar 1-2 g for solublization. Then kept  it for sterilization in 
autoclave for 1210C for 15 min. The petri plates were cleaned, sterilized and marked. These 
medium (Muller Hinton agar) were poured into petri-plates under aseptic conditions and  
allowed to solidify. Standardized bacterial inoculum was  spread uniformly over the surface 
of medium by using a sterile non-absorbent cotton swab and finally the swab was passed 
around the edge of the medium. The inoculated petri plates were closed with the lid and 
allowed to dry at room temperature. The sample impregnated discs and standard discs were 
placed on the inoculated agar medium. All petriplates were incubated at 370C for 24 h. After 
the incubation, diameter of zone of inhibition produced by the sample and standard was 
measured. The details are tabulated in Table 7 and Fig 32- 40 
5.1.2 ANTIFUNGAL SCREENING (Disc diffusion method) 
The antifungal activities of synthesized compounds were screened in the concentration of 
1µg/µl in dimethyl sulphoxide (DMSO) against the listed fungal strains, obtained from 
National Collection of Industrial Microorganisms (NCIM), Pune and Microbial Type Culture 
Collection (MTCC), Chandigarh, in the Sabourand’s Dextrose Broth by disc diffusion 
method using  Clotrimazole (10 µg disc) as standard. The antifungal activity was evaluated 
by measuring zone of inhibition in mm. 
Table 4. List of fungal strains used in the study 
Candida albicans MTCC 3100 
Monascus purpureus MTC 1090 
Aspergillus niger NCIM 1207 
Trichophyton rubrum MTCC 3272 
 
5.1.2.1 PREPARATION OF INOCULUMS 
Preparation of inoculums of fungus was carried out by Sabourand’s Dextrose Broth and 
transferred to test tube and kept it for sterilization in autoclave at 1200 C for 15 min. Then 
added culture of each fungal to each tube  (this step was carried out in aseptic room near 
laminar air flow) then kept it for incubation in incubator for 24-48 h at 290 C. 
5.1.2.2 PROCEDURE 
Sabourand’s Dextrose agar medium  was prepared by dissolving  1 gm of peptone and 4 gm 
of dextrose  in 100 ml of distilled water and  agar-agar 1-2 gm for solublization. Then kept  it 
for sterilization in autoclave for 1210 C for 15 min. The petri plates were cleaned, sterilized 
and marked. These medium (Sabourand’s Dextrose agar) were poured into petri-plates under 
aseptic conditions and  allowed to solidify. Standardized fungal inoculum was  spread 
uniformly over the surface of medium by using a sterile non-absorbent cotton swab and 
finally the swab was passed around the edge of the medium. The inoculated petri plates were 
closed with the lid and allowed to dry at room temperature. The sample impregnated discs 
and standard discs were placed on the inoculated agar medium. All petriplates were incubated 
at 290C for 24 - 48 h. After the incubation, diameter of zone of inhibition produced by the 
sample and standard was measured. The details are tabulated in Table 8 and Fig. 41- 49. 
 
 
 
 
 
 
 
 
 
5.1.3 MIC STUDIES 
5.1.3.1 PROCEDURE FOR DETERMINATION OF MINIMUM INHIBITORY 
CONCENTRATION FOR SYNTHESIZED COMPOUNDS AGAINST BACTERIA BY 
BROTH DILUTION METHOD 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by 
using Muller Hinton broth using the method described below. 
1. The tubes were labeled 1 to 8 and 1 ml of Muller Hinton broth was added to the first 5 
tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 7th tubes.  
2. One ml of different synthesized compounds was added to the 1st tube, mixed and 
transferred 1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so 
that each tube, 1 to 7 contained 1 ml diluted extract. The 8th tube served as the 
control.  
3. With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01 ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 37 0 C for 18 h. 
4. After incubation the turbidity was observed. The highest dilution of particular 
compounds showing no turbidity  and recorded. This was taken as the end point, and 
this dilution was considered to contain the concentration of drug equivalent to MIC. 
(Table 9 and Fig. 50- 52) 
 
 
 
 
 
 
 
 
5.1.3.2 PROCEDURE FOR DETERMINATION OF MINIMUM INHIBITORY 
CONCENTRATION FOR SYNTHESIZED COMPOUNDS AGAINST FUNGI BY 
BROTH DILUTION METHOD 
The serial dilution of compound solutions were made from the stock (1000 µg/ml) by 
using Sabourand’s dextrose broth using the method described below. 
1. The tubes were labeled 1 to 8 and 1 ml of Sabourand’s dextrose broth was added to 
the first 5 tubes and 8th tube, and then added 0.5 ml Muller Hinton broth to 6th and 
7th tubes.  
2. One ml of different synthesized compounds was added to the 1st tube, mixed and 
transferred 1 ml serially up to tube 6. Mixed and transferred 0.5 ml to the 7th tube so 
that each tube, 1 to 7 contained 1 ml diluted extract. The 8th tube served as the 
control.  
3. With a standardized micro pipette, added a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 270 C for 24 - 48 h. 
4. The highest dilution of particular compounds showing no turbidity was observed and 
recorded. This was taken as the end point, and this dilution was considered to contain 
the concentration of drug equivalent to MIC. (Table 10 and Fig. 53- 55) 
 
 
 
 
 
 
 
 
 
 
 5.2 ANTITUBERCULAR SCREENING 
Conventional methods like agar diffusion technique for susceptibility tests, which were based 
on the size of zone of inhibition surrounding a drug-containing disc, are not suitable for the 
slowly growing mycobacterium species because the drug diffuses throughout the medium 
before the organism grows.  
Susceptibility testing: Direct method and indirect method 
Direct method 
This was done in case where acid-fast bacilli are seen on the smear of the concentrated 
clinical specimen. Dilutions are made and inoculated. 
Indirect method 
In this method bacterial mass is suspend in middle Brook 7H9 broth containing 3 or 4 small 
sterile glass beads. Mixture is placed on a vortex mixer and precautions are taken to prevent 
aerosol production. Tube was allowed to stand for 15min. The stock suspensions were diluted 
and 0.1 ml was inoculated onto control and drug containing media.[87] 
 
5.2.1 RESAZURIN MICROTITRE PLATE ASSAY (REMA) 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is a blue dye, itself nonfluorescent 
until it is reduced to the pink colored and highly red fluorescent resorufin by oxidoreductases 
within viable cells.  It is used mainly as an oxidation-reduction indicator in cell viability 
assays for bacteria and mammalian cells, the principle being that resazurin does not fluoresce 
when exposed to green light while resorufin fluoresces. 
 
5.2.2 PROCEDURE 
The anti-TB activity of the compounds was tested by resazurin microplate assay as per 
Martin et al[88] with slight modification. M. tuberculosis H37Rv was grown in Middlebrook 
7H9 broth (Difco BBL, Sparks, MD, USA) supplemented with 10 % OADC (Becton 
Dickinson, Sparks, MD, USA) and 0.5% glycerol. The optical density of the bacterial culture 
was adjusted to McFarland 1.0 unit and 50 µl from this suspension was used as the 
inoculums. Stock solutions of the test compounds were prepared in dimethyl formamide 
(DMF) and were added to fresh medium in the wells of a 96-well microplate to which 50 µl 
inoculum was added making the total assay volume 200 µl. The final concentrations of the 
test molecules were 1, 10 and 100 µg/ml. Growth control wells contained medium and M. 
tuberculosis H37Rv alone. Rifampicin (1.0 µg/ml) served as positive control for inhibition of 
growth. Negative control wells contained the highest volume of DMF used in test wells 
without any compound. After incubation at 37ºC for 7 days, 15 µl of 0.01% resazurin (Sigma, 
St. Louis. MO, USA) solution in sterile water was added to the first growth control wells and 
incubated for 24 h. Once the first set of growth controls turned pink, the dye solution was 
added to the second set of growth controls and the test wells, and incubated for 24 h at 37ºC. 
Blue color in the wells containing the test compounds indicated inhibition of growth and pink 
indicated lack of   inhibition of growth      of M. tuberculosis. The details are tabulated in 
Table 11 and Fig 56. 
5.3 IN VITRO ANTIOXIDANT STUDIES 
An antioxidant is the one capable of slowing or preventing the oxidation where it protects the 
cell damage by reactive oxygen species that are produced during redox reactions in the cell. 
Antioxidants found in the body can be small molecules such as glutathione, vitamins, or 
macromolecules such as catalase (CAT), glutathione peroxidase (GPx). As oxidative stress 
contributes to the development of many diseases including Alzheimer's disease, Parkinson's 
disease, diabetes, rheumatoid arthritis and neurodegeneration, the use of antioxidants in 
pharmacology is intensively studied.[89] The antioxidant assays can roughly be classified into 
two types:  
A) Assays based on hydrogen atom transfer (HAT) reactions  
The majority of HAT-based assays apply a competitive reaction scheme, in which antioxidant 
and substrate compete for thermally generated peroxyl radicals through the decomposition of 
azo compounds. Some examples of such assays include inhibition of induced low-density 
lipoprotein autoxidation, oxygen radical absorbance capacity (ORAC), total radical trapping 
antioxidant parameter (TRAP) and crocin bleaching assays. 
B) Assays based on electron transfer (ET)  
These assays measure the capacity of an antioxidant in the reduction of an oxidant, which 
changes color when reduced. The sample's antioxidant concentration is correlated with the 
degree of its color change. Examples of such assays include the total phenols assay by Folin-
Ciocalteu reagent (FCR), Trolox equivalence antioxidant capacity (TEAC), ferric ion 
reducing antioxidant power (FRAP), "total antioxidant potential" assay using a Cu(II) 
complex as an oxidant and DPPH radical scavenging assay. 
In addition, there are also other assays intended to measure a sample's scavenging capacity of 
biologically relevant oxidants such as singlet oxygen, superoxide anion, peroxynitrite etc.[90] 
In-vitro Anti-oxidant screening of synthesized compounds were done by using two methods  
 
9 DPPH method 
9 FRAP method   
5.3.1 DPPH RADICAL SCAVENGING METHOD 
The free radical scavenging activity of a compound determined by this method is based on a 
reaction between a chomogen compound and antioxidant, and the concentration of the 
chomogen which is unreacted determined spectrophotometrically or colorimetrically. Most 
often used chomogen compound is DPPH (2,2-Diphenyl-1-Picryl-hydrazyl). 
5.3.1.1 REAGENTS USED 
Radical          : DDPH 
Solvent          : Ethanol 
Standard       : Ascorbic acid 
5.3.1.2 PREPARATION OF 0.3 mM DPPH  SOLUTION 
It was prepared by dissolving DPPH (5.91 mg) in 50 ml of ethanol. This stock solution was 
prepared freshly and kept in the dark at ambient temperature when not used. 
5.3.1.3 PREPARATION OF SAMPLE STOCK SOLUTION 
The sample stock solution was prepared by dissolving the compound in suitable solvent 
(ethanol) with a final concentration of 1 mg/ml. 
5.3.1.4 PREPARATION OF STANDARD STOCK SOLUTION 
The standard stock solution was prepared by dissolving the Ascorbic acid in suitable solvent 
(ethanol) with a final concentration of 1 mg/ml. 
5.3.1.5 PROCEDURE 
The effect of compound on DPPH radical was assayed using the method of Mensor et al[91]. 
Sample stock solutions (1.0 mg/ml) were diluted to appropriate final concentrations in 
ethanol. An ethanolic solution of 1 ml of DPPH (0.3 mM) was added to 0.5 ml of the 
compound and allowed to react at room temperature in a dark place for 30 minutes. After 30 
minutes the absorbance values were measured at 518 nm. All the measurements were taken 
as a triplicate values. From the average of the absorbance values, lower absorbance of the 
reaction mixture indicates higher free radical scavenging activity. The DPPH radical 
scavenging capability was calculated using the following equation: 
 
 
Where, 
ABS Control=Absorbance of ethanol+DPPH 
ABS Test     =Absorbance of DPPH + Compound /Standard 
The percentage antioxidant activity (% inhibition) was extrapolated against concentration of 
the compound and EC50 was determined graphically. The results are tabulated in Table 12 
and Fig. 57- 61. 
 
 
 
 
 
 
 
 
 
% inhibition = (ABS control – ABS test) /ABS control × 100 
5.3.2 FRAP RADICAL SCAVENGING METHOD 
FRAP (Ferric Reducing Ability of Plasma) is one of the most rapid test and very useful for 
routine analysis. The antioxidative activity is estimated by measuring the increase in 
absorbance caused by the formation of ferrous ions from FRAP reagent containing TPTZ (2, 
4, 6 – tri (2 – pyridyl) – s – triazine) and FeCl36H2O.[92] 
5.3.2.1 REAGENTS USED 
Radical      :  FRAP 
Solvent      :  Ethanol  
Standard    :  Ferrous sulphate   
5.3.2.2 PREPARATION OF FRAP REAGENT 
FRAP reagent was prepared by mixing10 parts of 300 mM sodium acetate buffer at pH 3.6, 1 
part of 10.0 mM TPTZ solution and 1 part of 20.0 mM FeCl3. 6H2O solution. 
5.3.2.3 PREPARATION OF TEST SOLUTION 
10 mg of each of the drug samples  were accurately weighed separately and dissolved in 1 ml 
of ethanol. These solutions were serially diluted with ethanol to obtain the lower dilutions. 
5.3.2.4 PREPARATION OF STANDARD SOLUTION 
10 mg of ferrous sulphate  were accurately weighed separately and dissolved in suitable 
solvent(water, ethanol). These solutions were serially diluted with ethanol to obtain the lower 
dilutions. 
5.3.2.5 PROCEDURE 
FRAP assay was carried out 0.2 ml of the compound is added to 3.8 ml of FRAP reagent and 
the reaction mixture was incubated at 37°C for 30 min and the increase in absorbance at 593 
nm is measured. FeSO4 is used for calibration. Quantitative calculation for each sample was 
done by plotting  linear calibration curve. The antioxidant activities were expressed as the 
concentration of antioxidants having a ferric reducing ability equivalent to that of 1 mM / l 
FeSO4. The equation used for Absorbance was as (y) = 0.274 x + 0.114 [r2 = 0.974]. The 
results are tabulated in Table 13 and Fig. 62- 65. 
5.4. IN VITRO ANTICANCER SCREENING 
Several approaches have been used in the past for the measurement of cell viability and 
growth. Though trypan blue staining is a simple way to evaluate cell membrane integrity (and 
thus assume cell proliferation or death), the method is not sensitive and cannot be adapted for 
high-throughput screening. The uptake of radioactive substances, usually tritium-labeled 
thymidine, can be measured. This method is accurate but is also time-consuming and 
involves handling of radioactive substances. 
5.4.1. MTT ASSAY 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), is 
reduced to purple formazan by mitochondrial succinate dehydrogenase in living cells. The 
MTT enters the cells and passes into the mitochondria where it is reduced to an insoluble, 
coloured (dark purple) formazan product. The insoluble purple formazan product is converted 
to a colored solution using a solubilization agent (usually either DMSO, an acidified ethanol 
solution, or a solution of the detergent sodium dodecyl sulfate in diluted hydrochloric acid). 
The absorbance of this colored solution is then quantified by measuring at a certain 
wavelength (usually between 500 and 600 nm) by a spectrophotometer. Since reduction of 
MTT can only occur in metabolically active cells, this assay gives a direct  measure of the 
viability of cells. 
5.4.2 PROCEDURE 
The human cervical cancer cell line (HeLa) was obtained from National Centre for Cell 
Science (NCCS), Pune. The cells were grown in Eagles Minimum Essential Medium 
containing 10% fetal bovine serum (FBS). 
For screening experiment, the cells were seeded into 96-well plates in 100 µl of medium 
containing 5% FBS, at plating density of 10,000 cells/well and incubated at 370C, 5% CO2, 
95% air and 100% relative humidity for 24 h prior to addition of samples. The samples were 
solubilized in Dimethylsulfoxide and diluted in serum free medium. After 24 h, 100 µl of the 
medium containing the samples at various concentration  (6.25, 12.5, 25, 50, and 100 µM ) 
were added and incubated at 370C, 5% CO2, 95% air and 100% relative humidity for 48 h. 
Triplicate was maintained and the medium containing without extracts were served as 
control. 
After 48 h, 15 µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was added to each 
well and incubated at 370C for 4 h. The medium with MTT was then flicked off and the 
formed formazan crystals were solubilized in 100 µl of DMSO and then measured the 
absorbance at 570 nm using micro plate reader. The % cell inhibition was determined using 
the following formula.  
  
 
Non linear regression graph was plotted between percentage cell inhibition and Log10 
concentration and IC50 was determined using GraphPad Prism software.[93,94]. The results are 
tabulated in Table 14 – 16 and Fig. 66- 81.          
              
 
    
 
 
 
 
 
 
 
 
 
 
 
% cell Inhibition = 100- Abs (sample)/Abs (control) x100 
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Table 5 . Physical and analytical data of synthesized compounds 
Code  
no 
 
Structure 
 
IUPAC  Name 
 
Melting 
range 
(oc) 
 
*Rf 
 
 
Molecular 
Formula 
 
Mol.wt 
 
Colour 
 
% 
Yield 
 
Solublity 
 
 
4a 
 
1-(3-chloro-2-oxo-
4-phenylazetidin-1-
yl)-3-(2-oxo-2-
(10H-phenothiazin-
10-yl)ethyl)urea 
 
 
106-110 
 
 
0.66 
 
 
C24H19ClN4O3S 
 
 
478.95 
 
 
Pale 
pink 
 
 
65.50 
 
 
DMSO, DMF, 
Acetone, 
 
 
 
4b 
 
1-(3-chloro-2-oxo-
4-styrylazetidin-1-
yl)-3-(2-oxo-2-
(10H-phenothiazin-
10-yl)ethyl)urea 
 
 
 
159-162 
 
 
 
0.69 
 
 
 
C26H21ClN4O3S 
 
 
 
504.99 
 
 
 
Green 
 
 
 
85.38 
 
 
DMSO, DMF, 
Dichloromethane 
 
 
4c 
 
1-(3-chloro-2-(4-
methoxyphenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
141-144 
 
 
 
0.49 
 
 
 
C25H21ClN4O4S 
 
 
 
508.98 
 
 
 
Bright 
green 
 
 
 
82.72 
 
 
 
DMSO, DMF, 
Ethyl acetate 
 
 
4d 
 
1-(3-chloro-2-(4-
(dimethylamino)ph
enyl)-4-oxozetidin-
1-yl)-3-(2-oxo-2-
(10H-phenothiazin-
10-yl)ethyl)urea 
 
 
 
170-173 
 
 
 
0.58 
 
 
 
C26H24ClN5O3S 
 
 
 
522.02 
 
 
 
Blackish 
brown 
 
 
 
71.11 
 
 
DMSO, DMF, 
Dichloromethane 
6.RESULTS 
  
 
 
 
4e 
 
1-(3-chloro-2-(4-
hydroxy-3-
methoxyphenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
150-155 
 
 
 
0.72 
 
 
 
C25H21ClN4O5S 
 
 
 
524.98 
 
 
 
Bluish 
green 
 
 
 
67.71 
 
 
DMSO, DMF, 
Ethyl acetate, 
Acetone 
 
 
4f 
 
1-(3-chloro-2-(4-
nitrophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
186-190 
 
 
 
0.65 
 
 
 
C24H18ClN5O5S 
 
 
 
523.95 
 
 
 
Black 
 
 
 
55.33 
 
 
DMSO, DMF, 
Dichloromethane 
Acetone 
 
 
4g 
 
 
 
 
 
 
 
1-(3-chloro-2-(2-
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
165-169 
 
 
 
 
 
 
0.63 
 
 
 
 
 
 
C24H18Cl2N4O3S 
 
 
 
 
 
 
 
513.4 
 
 
 
 
 
 
Pink 
 
 
 
 
 
 
76.44 
 
 
 
 
 
 
DMSO, DMF, 
Acetone, 
Dichloromethane, 
Ethyl acetate 
 
 
4h 
 
1-(3-chloro-2-(4- 
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
165-167 
 
 
 
0.54 
 
 
 
C24H18Cl2N4O3S 
 
 
 
513.4 
 
 
 
Pale 
brown 
 
 
 
79 
 
 
DMSO, DMF, 
Acetone, 
Dichloromethane 
  
 
 
4i 
 
1-(3-chloro-2-(4-
hydroxyphenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
149-152 
 
 
0.76 
 
 
C24H19ClN4O4S 
 
 
494.95 
 
 
Pale 
green 
 
 
66.07 
 
 
DMSO, DMF, 
Dichloromethane 
 
 
4j 
 
1-(3-chloro-2-(3-
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
155-160 
 
 
0.55 
 
 
C24H18Cl2N4O3S 
 
 
513.4 
 
 
Green 
 
 
69.33 
 
 
DMSO, DMF, 
Dichloromethane 
 
 
4k 
 
1-(3-chloro-2-(3-
fluorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)urea 
 
 
 
168-172 
 
 
 
0.58 
 
 
 
C24H18ClFN4O3S 
 
 
 
496.94 
 
 
 
Pale 
pink 
 
 
 
72.86 
 
 
 
DMSO, DMF, 
Acetone 
 
 
7a 
 
1-(3-chloro-2-oxo-
4-phenylazetidin-1-
yl)-3-(2-oxo-2-
(10H-phenothiazin-
10-
yl)ethyl)thiourea 
 
 
106-110 
 
 
0.66 
 
 
C24H19ClN4O2S2 
 
 
495.02 
 
 
Green 
 
 
82 
 
 
DMSO, DMF, 
Ethyl acetate, 
Acetone 
 
 
7b 
 
1-(3-chloro-2-oxo-
4-styrylazetidin-1-
yl)-3-(2-oxo-2-
(10H-phenothiazin-
10-
yl)ethyl)thiourea 
 
 
 
116-120 
 
 
 
0.5 
 
 
 
C26H21ClN4O2S2 
 
 
 
521.05 
 
 
 
yellow 
 
 
 
63.87 
 
 
 
DMSO, DMF, 
Dichloromethane 
  
 
 
7c 
 
1-(3-chloro-2-(4-
methoxyphenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
136-140 
 
 
 
0.63 
 
 
 
C25H21ClN4O3S2 
 
 
 
525.04 
 
 
 
Brown 
 
 
 
59.82 
 
 
 
DMSO, DMF, 
Ethyl acetate 
 
 
7d 
 
1-(3-chloro-2-(4-
(dimethylamino)ph
enyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
160-163 
 
 
 
0.79 
 
 
 
C26H24ClN5O2S2 
 
 
 
538.08 
 
 
 
Brown 
 
 
 
82.1 
 
 
DMSO, DMF, 
Dichloromethane 
 
 
7e 
 
1-(3-chloro-2-(4-
(dimethylamino)ph
enyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
156-162 
 
 
 
0.71 
 
 
 
C26H24ClN5O2S2 
 
 
 
541.04 
 
 
 
Yellow 
 
 
 
55.60 
 
 
 
DMSO, DMF, 
Acetone,  
Dichloromethane 
 
 
7f 
 
1-(3-chloro-2-(4-
nitrophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H 
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
115-119 
 
 
 
0.68 
 
 
 
C24H18ClN5O4S2 
 
 
 
 
540.01 
 
 
 
Greyish 
green 
 
 
 
80.7 
 
 
DMSO, DMF, 
Dichloromethane, 
Acetone 
 
 
7g 
 
1-(3-chloro-2-(2-
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
118-123 
 
 
 
0.66 
 
 
 
C24H18Cl2N4O2S2 
 
 
 
529.46 
 
 
 
Cream 
yellow 
 
 
 
81.53 
 
 
DMSO, DMF, 
Dichloromethane, 
Ethyl acetate 
  
 
 
7h 
 
1-(3-chloro-2-(4-
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
 
143-149 
 
 
 
0.71 
 
 
 
C24H18Cl2N4O2S2 
 
 
 
529.46 
 
 
 
Green 
 
 
 
83.75 
 
 
DMSO, DMF, 
Dichloromethane, 
Acetone 
 
 
7i 
 
1-(3-chloro-2-(4-
hydroxyphenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
145-153 
 
 
0.72 
 
 
C24H19ClN4O3S2 
 
 
511.02 
 
 
Green 
 
 
65.06 
 
 
DMSO, DMF, 
Ethyl acetate, 
Acetone 
 
 
 
7j 
 
1-(3-chloro-2-(3-
chlorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
108-112 
 
 
0.56 
 
 
C24H18Cl2N4O2S2 
 
 
529.46 
 
 
Grayish 
green 
 
 
54.01 
 
 
DMSO, DMF, 
Dichloromethane, 
Acetone 
 
 
7k 
 
1-(3-chloro-2-(3-
fluorophenyl)-4-
oxoazetidin-1-yl)-
3-(2-oxo-2-(10H-
phenothiazin-10-
yl)ethyl)thiourea 
 
 
118-125 
 
 
0.62 
 
 
C24H18ClFN4O2S2 
 
 
513.01 
 
 
Yellow 
 
 
52.53 
 
 
DMSO, DMF, 
Dichloromethane, 
Ethyl acetate 
 
*MOBILE PHASE: 4a-k, 7a-k  - benzene:chloroform (1:9) 
  DETECTING AGENT: 4a-k, 7a-k- iodine vapours. 
  
Table 6. Spectral data of synthesized compounds 
 
CODE 
(DMSO, λmax, nm) 
IR 
(KBr, v, cm-1) 
1H NMR 
(DMSO, δ, ppm) 
 
EIMS 
(M+) 
 
 
4a 
3340 (NH stretching) 
3167,1596,736, (aromatic stretching) 
1718 (C=O stretching) 
1472 (C-N stretching), 811(C-Cl) 
700(C-S-C stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
4b 
3135 (NH stretching) 
2921,1599,697 (aromatic stretching) 
1695 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1444 (C-N stretching), 919 (CH=CH 
stretching) 811 (C-Cl) 756 (C-S-C 
stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
4c 
3340(NH stretching) 
3133, 736 (aromatic stretching) 
1597 (C=O stretching 
1596 and 1570 (phenothiazine ring), 
1401 (C-N stretching) 
1253 (C-O-C), 832(C-Cl) 
686(C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
4d 
3410 (NH stretching) 
3150,1542,737 (aromatic stretching) 
1620 (C=O stretching), 1596 and 1570 
(phenothiazine ring),1470 (C-N 
stretching), 1312 (CN of N(CH3)2 
827 (C-Cl stretching), 686 (C-S-C 
stretching) 
6.59-7.0 (m,12H, Ar-H) 
2.9 (s,6H,N(CH3)2) 
3.4 (s,2H,CH2) 
2.5(d,1H,C-CH-Cl) 
azetidinone ring 
8.5 (s, 1H,NH)  
NH2 not detectable 
 
 
 
- 
 
 
 
4e 
 
 
 
 
3340 (OH stretching), 3154 (NH 
stretching), 2932, 1595,736 (aromatic 
stretching), 1750(C=O stretching) 
1596 and 1570(phenothiazine ring), 
1120  (C-O-C stretching) 
1400 (C-N stretching) 
821 (C-Cl), 686(C-S-C stretching) 
 
 
 
 
 
- 
 
 
 
 
 
524.9 
 
 
 
 
 
 
 
 
4f 
3490 (NH stretching) 
3134,1578,736 (aromatic stretching 
1699 (C=O stretching), 1596 and 1570 
(phenothiazine ring), 1517,1341 (N=O 
stretching)1467 (C-N stretching) 
816 (C-Cl),688 (C-S-C stretching) 
 
 
 
- 
 
 
 
- 
  
 
 
 
4g 
3346 (NH stretching) 
3127,1578,737 (aromatic stretching) 
1721 (C=O stretching) 
1596 and 1570 
(phenothiazine ring), 
1463 (C-N stretching) 
816 (C-Cl stretching) 
688 (C-S-C stretching) 
6.52-7.26 (m,12H,Ar-
H), 3.32 (s,2H,CH2) 
2.5 (d,1H,C-CH-Cl) 
azetidinone ring 
7.4-7.8 (m,2H,+2H,Ar-
H) o-chloro phenyl 
ring, 8.5(s,1H,NH), 
NH2 not detectable 
 
 
 
- 
 
 
 
4h 
3340 (NH stretching) 
3133,1517,737 (aromatic stretching) 
1596 and 1570(phenothiazine ring), 
1596 (C=O stretching) 
1470 (C-N stretching) 
821(C-Cl) 
655 (C-S-C stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
4i 
3340 (OH stretching) 
3132(NH stretching) 
2920,1512,737,(aromatic stretching) 
1596 and 1570 
(phenothiazine ring), 
1596 (C=O stretching) 
1470 (C-N stretching) 
827 (C-Cl), 686 (C-S-C stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
4j 
3346 (NH stretching) 
3127,1595,736 (aromatic stretching) 
1671(C=O stretching) 
1596 and 1570(phenothiazine ring) 
1460 (C-N stretching) 
837(C-Cl) 
656(C-S-C stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
4k 
3346 (NH stretching) 
2920,1596,736(aromatic stretching) 
1718 (C=O stretching) 
1596 and 1570 (phenothiazine ring), 
1472 (C-F stretching) 
1401(C-N stretching) 
876(C-Cl) 
656(C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
 
  
 
 
 
 
 
7a 
3340(NH stretching) 
3134,737 (aromatic stretching) 
1596 (C=O stretching) 
1472 (C-N stretching) 
1112 (C=S attached NH) 
827(C-Cl), 689 (C-S-C stretching) 
 
 
 
- 
 
 
 
- 
 
 
 
7b 
3340(NH stretching) 
3132,738(aromatic stretching) 
1596 (C=O stretching) 
1400(C-N) 
1132 (C=S attached NH 
968(CH=CH stretching), 
827(C-Cl), 689 (C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
7c 
3340(NH stretching) 
3111,1533,754 (aromatic stretching) 
1670 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1518,1151(C=S linked to NH) 
1400 (C-N stretching), 1188 (C-O-C) 
836 (C-Cl), 690 (C-S-C stretching) 
6.68-7.14 (m,12H,Ar-H) 
3.3 (s,3H,OCH3) 
3.7 (s,2H,CH2) 
2.5 (d,1H,C-CH-Cl) 
azetidinone ring,  
NH and NH2 not 
detectable 
 
 
 
 
 
 
- 
 
 
 
 
7d 
3340(NH stretching) 
3160,1524,736 (aromatic stretching) 
1599 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1512,1089 (C=S linked to NH) 
1472 (C-N stretching),1311 (CN of 
N(CH3)2, 817 (C-Cl) 
716(C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
 
7e 
3340 (OH stretching) 
3135 (NH stretching) 
2918,1596,736 (aromatic stretching) 
1600(C=O) 
1596 and 1570(phenothiazine ring), 
1512,1122 (C=S attached NH) 
1083 (C-O-C)) 
1400(C-N stretching) 
827(C-Cl) 
716(C-S-C stretching) 
 
6.68-7.0 (m,11H,Ar-H) 
3.3 (s,3H,OCH3) 
3.4 (s,1H,OH) 
2.5 (d,1H,C-CH-Cl) 
azetidinone ring 
8.5(s,1H, NH) 
NH2 not detectable 
 
 
 
 
 
 
- 
  
 
 
 
7f 
3128 (NH stretching) 
2918,1595,748 (aromatic stretching) 
1600 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1515,1342(N=Ostretching),1468,1117 
(C=S linked to NH) 
1401 (C-N stretching) 
837(C-Cl), 656(C-S-C stretching) 
 
 
 
- 
 
 
 
541.11 
 
 
 
7g 
3340(NH stretching) 
3148,1594,736 (aromatic stretching) 
1694 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1532,1105 (C=S linked to NH) 
1401(C-N stretching) 
821(C-Cl), 686(C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
7h 
3340 (OH stretching) 
3135 (NH stretching) 
2918,1596,736(aromatic stretching) 
1600 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1512,1122 (C=S linked to NH) 
1400 (C-N stretching) 
716 (C-Cl), 686 (C-S-C stretching) 
6.-7.4 (m,12H,Ar-H) 
3.3 (s,2H, CH2) 
7.7-7.8 (m,2H,+2H,Ar-
H) P-chloro phenyl ring. 
2.5 (d,1H,C-CH-Cl) 
azetidinone ring 
8.6 (s1H, NH)  
NH2 not detectable. 
 
 
 
 
- 
 
 
 
7i 
3341 (OH stretching) 
3147 (NH stretching) 
2918,1596,738 (aromatic stretching) 
1596 and 1570(phenothiazine ring), 
1650 (C=O stretching) 
1510,1136 (C=S linked to NH) 
1401(C-N stretching),716 (C-Cl) 
655 (C-S-C stretching) 
 
 
 
 
- 
 
 
 
 
- 
 
 
 
7j 
3339 (NH stretching) 
3131,1570,730 (aromatic stretching) 
1595 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1472,1185 (C=S linked to NH) 
1401 (C-N stretching) 
876 (C-Cl),655 (C-S-C stretching) 
 
 
 
 
- 
 
 
- 
 
 
 
 
7k 
3340 (NH stretching) 
3113,1582,754 (aromatic stretching) 
1670 (C=O stretching) 
1596 and 1570(phenothiazine ring), 
1519, 1151(C=S linked to NH) 
1471 (C-F stretcting) 
3336 (C-N stretching) 
837 (C-Cl) 
626 (C-S-C stretching) 
6.6-7.0(m,12H,Ar-H) 
7.3-7.5 (m,4H,Ar-H) 
flouro substituted phenyl 
ring. 
3.5(s,2H,CH2) 
2.5(d,1H,C-CH-Cl) 
azetidinone ring 
8.7(s,1H, NH)  
NH2 not detectable. 
 
 
- 
  
 
Fig 2. IR spectrum of compound 4a 
 
 
 
Fig 3. IR spectrum of compound 4b 
  
 
Fig 4. IR spectrum of compound 4c 
 
 
 
Fig 5. IR spectrum of compound 4d 
 
  
 
Fig 6. IR spectrum of compound 4e 
 
 
 
Fig 7. IR spectrum of compound 4f 
 
  
 
Fig 8. IR spectrum of compound 4g 
 
 
 
Fig 9. IR spectrum of compound 4h 
 
  
 
Fig 10. IR spectrum of compound 4i 
 
 
 
Fig 11. IR spectrum of compound 4j 
 
  
 
Fig 12. IR spectrum of compound 4k 
 
 
 
Fig 13. IR spectrum of compound 7a 
 
  
 
Fig 14. IR spectrum of compound 7b 
 
 
 
Fig 15. IR spectrum of compound 7c 
 
  
 
Fig 16. IR spectrum of compound 7d 
 
 
 
Fig 17. IR spectrum of compound 7e 
  
 
Fig 18. IR spectrum of compound 7f 
 
 
 
Fig 19. IR spectrum of compound 7g 
 
  
 
Fig 20. IR spectrum of compound 7h 
 
 
 
Fig 21. IR spectrum of compound 7i 
  
 
Fig 22. IR spectrum of compound 7j 
 
 
 
Fig 23. IR spectrum of compound 7k 
 
  
  
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
  
  
  
  
 
  
  
 
  
  
  
ANTIBACTERIAL STUDIES 
 Table 7.  Antibacterial screening of titled compounds by disc diffusion method 
 
 
Code 
ZONE OF INHIBITION in mm 
E.coli P.auroginosa S.paratyphyi V.chlorea M.luteus S.aureus B.subtilis S.albus 
4a 7 5 5 7 4 - 6 7 
4b 5 7 7 6 5 3 5 8 
4c 7 8 8 9 7 5 7 10 
4d 12 7 6 8 5 8 8 8 
4e 10 10 10 10 8 7 6 5 
4f - 15 7 5 3 4 5 4 
4g 7 8 12 6 7 4 7 5 
4h 5 19 5 18 5 4 7 5 
4i 18 5 12 9 12 9 10 13 
4j 10 5 10 8 5 7 11 11 
4k 11 6 10 9 7 7 11 11 
7a 12 8 11 10 14 10 12 10 
7b 7 5 14 9 6 10 8 7
7c 9 7 6 12 4 14 15 8 
7d 5 6 7 12 6 12 6 8 
7e 8 9 5 8 6 7 12 9 
7f 7 12 7 5 10 20 13 6 
7g 12 10 10 8 10 10 12 10 
7h 14 11 9 7 11 7 12 15 
7i 7 12 11 7 8 7 11 7
7j 18 12 13 10 8 12 10 11 
7k 19 15 11 9 7 11 11 13 
Ciprofloxacin 22 20 18 15 16 20 25 23 
 
                      4a-k, 7a-k = synthesized compounds in the concentration of 10 µg/disc, Ciprofloxacin in the concentration of 5 µg/disc
  
                    
 
 
 
 
                      
 
 
 
 
                      
  
Fig 32 . Antibacterial 
evaluation of compounds  
 4i-k,7a  against E.coli 
Fig 34 . Antibacterial 
evaluation of compounds 
 7e-h against S.paratyphyi 
Fig 33 . Antibacterial 
evaluation of compounds 
 7b-e against P.auroginosa 
Fig 35. Antibacterial 
evaluation of compounds   
4i-k, 7a against V.chlorea 
Fig 36 . Antibacterial 
evaluation of compounds   
4i-k, 7a against M.luteus 
Fig 37 . Antibacterial 
evaluation of compounds  
7i-j against M.luteus 
Fig 38. Antibacterial 
evaluation of compounds 
 4e-h against S.aureus 
Fig 39 . Antibacterial 
evaluation of compounds  
7i-j against B.subtilis 
Fig 40. Antibacterial 
evaluation of compounds  
4a-d against S.albus 
  
 
ANTIFUNGAL SCREENING 
                           Table 8. Antifungal screening of titled compounds by disc diffusion method 
   Code  ZONE OF INHIBITION in mm 
       C.albicans M.purpurea      A.niger     T.rubrum 
4a 6 3 4 4 
4b 8 6 6 8 
4c 7 6 10 6 
4d 7 7 8 7 
4e 10 7 5 4 
4f 14 13 9 5 
4g 12 10 8 10 
4h 7 12 12 6 
4i 13 10 8 8 
4j 12 7 7 6 
4k 11 10 7 7 
7a 12 10 7 4 
7b 4 5 4 4 
7c 8 8 8 4 
7d 8 12 4 16 
7e 9 10 8 8 
7f 5 5 6 6 
7g 8 10 8 6 
7h 6 13 14 7 
7i 5 10 6 6 
7j 10 8 10 5 
7k 13 6 4 6 
std - 20 4 22 
 
          4a-k, 7a-k= synthesized compounds in the concentration of 10 µg/disc 
          std   = Clotrimazole in the concentration of 10 µg/disc 
 
 
 
 
 
 
 
 
  
 
                    
 
   
 
               
 
 
 
                   
 
 
 
   
Fig 41 . Antifungal  
evaluationof compounds  
4e-h against  C.albicans 
Fig 42 . Antifungal  
evaluation of compounds  
4i-k,7a against   C.albicans 
Fig 43. Antifungal  
evaluationof compounds 
7j-k against C.albicans 
Fig 45. Antifungal 
 evaluation of compounds  
4i-j against M.purpurea 
Fig 44. Antifungal 
 evaluation of compounds 
4e-h against  M.purpurea      
Fig 46. Antifungal  
evaluation of compounds  
4e-h against A.niger 
Fig 47. Antifungal 
Evaluation of compounds  
7f-i against A.niger 
Fig 48. Antifungal 
 Evaluation of compounds  
4i-k,7a against T.rubrum 
Fig 49. Antifungal 
Evaluation of compounds  
7b-e against T.rubrum     
  
 
 
  MIC STUDIES 
 Table 9 . Minimum inhibitory concentration of synthesized compounds against bacteria    
by broth dilution method 
 
Code 
                                                         MIC (µg/ml)
E.coli P.auroginosa S.paratyphyi V.chlorea M.luteus S.aureus B.substilis S.albus 
4a 250 500 500 250 250 250 250 250 
4b 125 250 125 125 250 500 250 125 
4c 125 125 125 125 250 250 250 62.5 
4d 62.5 250 250 125 250 125 125 125 
4e 125 125 125 125 250 250 250 250 
4f 500 62.5 125 250 250 250 250 250 
4g 250 250 125 250 250 500 250 250 
4h 250 62.5 250 62.5 250 62.5 125 250 
4i 62.5 250 62.5 125 62.5 125 125 125 
4j 125 500 125 250 250 250 125 125 
4k 125 250 125 125 250 250 62.5 125 
7a 62.5 250 250 250 250 250 250 250 
7b 250 500 62.5 250 250 125 125 125 
7c 125 250 250 125 500 62.5 62.5 125 
7d 250 250 250 125 250 125 250 250 
7e 125 125 500 125 250 250 125 125 
7f 250 125 250 250 125 62.5 125 250 
7g 125 125 125 125 125 125 125 125 
7h 62.5 125 125 125 125 125 125 62.5 
7i 250 125 250 250 250 250 125 250 
7j 62.5 125 125 250 250 250 125 125 
7k 62.5 62.5 125 250 250 125 125 125 
Std 62.5 62.5 125 125 125 62.5 62.5 62.5 
 
Std- Ciprofloxacin 
 
 
 
 
 
 
 
  
 
Fig 50.Antibacterial actvity of compound 4h  showed MIC at 62.5µg/ml 
 against E.coli 
   
Fig 51. Antibacterial activity  of compound 7f showed MIC  at 62.5µg/ml  
against B.substilis 
     
Fig 52. Antibacterial activity of compound 7k   showed MIC at 62.5µg/ml  
against S.aureus 
  
 
 Table 10 .  Minimum inhibitory concentration of synthesized compounds against fungi 
by broth dilution method 
Code                                           MIC (µg/ml) 
       C.albicans    M.purpurea      A.niger     T.rubrum 
4a 500 250 250 250 
4b 250 250 250 125 
4c 250 250 125 250 
4d 250 250 125 250 
4e 125 250 250 250 
4f 62.5 62.5 500 250 
4g 62.5 125 125 125 
4h 125 62.5 125 250 
4i 62.5 500 62.5 250 
4j 62.5 250 250 250 
4k 125 125 250 125 
7a 125 125 250 250 
7b 250 250 500 250 
7c 250 250 250 250 
7d 250 62.5 250 62.5 
7e 250 125 250 125 
7f 500 250 250 125 
7g 250 125 250 125 
7h 500 62.5 62.5 62.5 
7i 250 125 250 250 
7j 125 250 125 250 
7k 125 250 125 250 
Std 62.5 62.5 125 62.5 
 
       Std- Clotrimazole 
 
 
 
 
 
 
  
 
Fig 53. Antifungal activity of compound 4f  showed MIC at 62.5µg/ml  
against C.albicans 
 
Fig 54. Antifungal activity of comound 4h  showed MIC at 62.5µg/ml  
against M.purpurea 
 
Fig 55. Antifungal activity of compound 7d  showed MIC at 62.5µg/ml  
against T.rubrum 
  
 
ANTITUBERCULAR STUDIES 
 Table 11. In vitro antitubercular screening by REMA 
No Compound Concentration µg/ml 
1 10 100 
1 4d N N P 
2 4f N N P 
3 4j N P P 
4 7h N P P 
5 7i N N N 
6 7k N P P 
7 std P P  
8 control N N  
        N = no inhibition 
        P = inhibition 
       Std= Rifampicin 
       
  
 
Fig 56. In vitro antitubercular screening by REMA. 
 
 
  
 
ANTIOXIDANT STUDIES 
 Table 12. DPPH radical scavenging activity of titled compounds 
Code Concentration % inhibition EC50 (µg/ml) 
 
4d 
25 40.01  
55 50 48.26 
                 75 69.71 
100                 86.62 
 
4e 
25 68.93  
- 50 85.78 
75 79.34 
100 80.83 
 
4g 
25 26.81  
63 50 43.08 
75 79.12 
100 88.76 
 
7c 
25 82.46  
- 50 86.68 
75 87.70 
100 91.59 
 
7e 
25 87.93  
- 50 92.10
75 90.86 
100 84.17 
 
7f 
25 91.71  
- 50 82.48 
75 89.32 
100 79.97 
 
7g 
25 33.34  
57 50 42.65 
75 74.82 
100 91.53 
 
7h 
25 21.20  
66 50 39.08 
75 64.10 
100 83.02 
 
7i 
25 85.54  
- 50 82.67 
75 72.67 
100 80.29 
 
7k 
25 25.1  
47 50 56.02 
75 70 
100 92.36 
STANDARD 
  (Ascorbic acid) 
25 45.7  
40 50 58.9 
75 81 
100 96 
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Table 13. FRAB radical scavenging activity of titled compounds 
Code Concentration Absorption R2 
 
4d 
25 0.3005  
0.956 50 0.3269 
              75 0.3368 
100 0.3732 
 
4e 
25 0.1481  
0.664 50 0.2983 
75 0.2081 
100 0.9089 
 
4g 
25 0.2751  
0.957 50 0.3393 
75 0.3639 
100 0.3981 
 
7c 
25 0.1832  
0.512 50 0.5312
75 0.3982 
100 0.5301 
 
7e 
25 0.0321  
0.637 50 0.0891 
75 0.0899 
100 1.2910
 
7f 
25 0.0184  
0.444 50 0.3265 
75 0.1037 
100 0.6493 
 
7g 
25 0.2751  
0.586 50 0.3393 
75 0.4119 
100 0.4723 
 
7h 
25 0.1533  
0.466 50 0.4736 
75 0.3147 
100 1.8951 
 
7i 
25 0.0691  
0.945 50 0.1031 
75 0.1143 
100 0.1582 
 
7k 
25 0.9163  
0.967 50 1.0568 
75 1.1043 
100 1.2076 
STANDARD 
  (Ferrous sulphate) 
25 0.9509  
0.981 50 1.0988 
75 1.1843 
100 1.2743 
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ANTICANCER STUDIES 
 Table 14. Absorbance of various concentrations of samples at 570 nm 
Code  Conc (µM ) 6.25  
 
12.5 25 50 100 Cont 
 
4f 
ABS 0.209 0.155 0.121 0.077 0.032 0.274 
 0.222 0.152 0.117 0.075 0.026 0.268 
 0.19 0.166 0.116 0.066 0.027 0.271 
Avg 0.207 0.157 0.118 0.074 0.028 0.271 
 
4h 
ABS 0.269 0.243 0.228 0.187 0.158 0.274 
 0.279 0.256 0.227 0.174 0.154 0.268 
 0.271 0.266 0.228 0.179 0.141 0.271 
Avg 0.270 0.255 0.227 0.180 0.151 0.271 
 
4i 
ABS 0.270 0.259 0.226 0.176 0.115 0.274 
 0.272 0.253 0.212 0.170 0.131 0.268 
 0.270 0.26 0.22 0.163 0.131 0.271 
Avg 
 
0.270 0.257 0.219 0.169 0.121 0.271 
 
 Table 15. Absorbance of various concentrations of samples at 570 nm 
 
Code  Conc (µM ) 0.1 
 
1     10 100 Cont  
 
7d 
ABS 0.387 0.392 0.102 0.053 0.371 
 0.408 0.405 0.113 0.060 0.417 
 0.393 0.386 0.117 0.048 0.407 
Avg 0.396 0.394 0.111 0.054 0.398 
 
7j 
ABS 0.39 0.362 0.307 0.132 0.371 
 0.40 0.361 0.311 0.143 0.417 
 0.376 0.372 0.277 0.121 0.407 
Avg 0.389 0.365 0.298 0.132 0.398 
 
7k 
ABS 0.336 0.318 0.20 0.105 0.371 
 0.346 0.304 0.179 0.107 0.417 
 0.361 0.305 0.216 0.113 0.407 
Avg 
 
0.347 0.305 0.198 0.108 0.398 
 
 
 
 
 
  
 
      Table 16 . Percentage cell inhibition produced by titled compounds at varying 
concentrations 
Code Conc (µM) % Cell Inhibition IC50 (µM) 
4f 
6.25 23.61624  
 
18.26 
12.5 41.82042 
25 56.45756
50 73.18573 
100 89.5449 
4h 
6.25 0.123001  
 
111.2 
12.5 5.904059 
25 15.91016 
50 33.57934 
100 44.28044 
4i 
6.25 0.123001  
 
84.11 
12.5 5.04305 
25 19.06519 
50 37.39237 
100 53.01353 
7d 
0.1 0.585774  
 
6.13 
1 1.004184 
10 72.21754 
100 86.5257 
7j 
0.1 2.426778  
 
40 
1 8.368201 
10 25.1046 
100 66.86192
 
7k 
0.1 12.71967  
 
11.09 
1 22.42678 
10 50.20921 
100 72.80335 
 
 
 
 
 
 
 
 
Fig 66. Graph plotted between the percentage growth inhibition and log concentration of compound 
4f (R2=0.9922) 
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Fig 67. Inhibition of HeLa by                          Fig 68. Inhibition of HeLa by                            
Compound 4f (6.5 µM)                              Compound 4f (12.5 µM) 
 
                                  
Fig 69. Inhibition of HeLa by                            Fig 70. Inhibition of HeLa by          
Compound 4f (25 µM)                                     Compound 4f (50 µM) 
                                                
                                                                                                                                                                               
    
 
       Fig 71. Inhibition of HeLa by  
Compound 4f (100 µM) 
  
  
                        
 
 
 
 
 
 
 
 
Fig 72. Graph plotted between the percentage growth inhibition and log concentration of  compound 
7d (R2=0.9724) 
 
                                
         Fig 73 . Inhibition of HeLa by                  Fig 74. Inhibition of HeLa by  
              Compound 7d (0.1 µM)                                compound 7d (1 µM) 
 
           
 
Fig 75. Inhibition of HeLa by                         Fig 76. Inhibition of HeLa by        
compound7d (10 µM)                                             compound 7d (100 µM) 
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Fig 77 . Graph plotted between the percentage growth inhibition and log concentration of compound 
7k (R2=0.9938) 
 
                 
          Fig 78. Inhibition of HeLa by                    Fig 79. Inhibition of HeLa by  
                   compound7k (0.1 µM)                      compound7k (1 µM) 
 
                                   
             Fig 80. Inhibition of HeLa by                Fig 81. Inhibition of HeLa by  
compound7k (10 µM)                         compound 7k (100 µM) 
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Chapter 7 
 
 
 
 
 
 
 
                       Discussion  
  
 
 
7.1 Chemistry 
Two different series with a total of 22 compounds of 1-(3-chloro-2-oxo-4-phenylazetidin-1-
yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea and thiourea derivatives have been 
synthesized.  
The derivatives were synthesized by a four step reaction as described in Scheme-I and  
Scheme-2. In the first step,  2-chloro-1-(10H-phenothiazin-10-yl)ethanone has been prepared 
from phenothiazine and chloroacetyl chloride  using  dry benzene as solvent followed by the 
treatment with semicarbazide/thiosemicarbazide to form 4-(2-oxo-2-(10H-phenothiazin-
10yl)ethyl) semicarbazide/thiosemicarbazide (step 2, 5). Schiff bases of phenothiazines were 
then synthesized by the condensation of 4-(2-oxo-2(10H-phenothiazin-10yl) 
semicarbazide/thiosemicarbazide with various substituted aromatic aldehydes (step 3, 6). 
Finally a series of substituted azetidinones have been synthesized by cyclocondensation of 
various Schiff bases of phenothiazine with chloroacetyl chloride in presence of triethyl amine 
(step 4, 7).   
All the titled compounds yielded the products in the range of 52-83%. The melting points of 
the compounds 4a-k, 7a-k were observed in the range of 110-1900C. All compounds showed 
only one spot of migration from the origin on TLC plates, thereby confirming their purity. 
7.2 Characterization 
All the newly synthesized compounds were characterized by FTIR and six selected 
compounds were characterized by 1HNMR and two selected compounds by Mass 
spectroscopic method. 
The  structure of intermediate compounds 3a-k and 6a-k  were confirmed by the presence of 
characteristic peaks in the regions of 1690 cm-1 for  C=O stretching, 3350 cm-1 for NH 
stretching, 3080,1600 and 790 cm-1 for aromatic stretching and1569 cm-1 for N=CH 
stretching . The compounds  5a-k, 6a-k, and 7a-k showed characteristic bands for C=S 
linked to NH at 1512, 1165 cm-1.  Compounds 4b-k and 7c-k confirmed the presence of 
phenothiazine ring due to the IR absorption bands in  the region 1596 and 1570 cm-1. The 
compounds of the  both series  4a-k and 7a-k  showed    characteristic peaks in the regions of 
7.DISCUSSION 
  
1657 cm-1 for  C=O  stretching for azetidinone, 3340 cm-1 for NH stretching, 3129 cm-1, 1592 
cm-1 and  737 cm-1 for aromatic stretching, 1467 cm-1 for C-N stretching and 827 cm-1 for C-
Cl stretching. Compounds containing NO2 group showed absorption bands at 1518, 1343 cm-
1 for the N=O stretching and the peaks at 650-740 cm-1 could be assigned to C-S-C stretching. 
Presence of hydroxyl group was confirmed by the appearance of broad peak at 3430-3161 
cm-1.  
Six synthesized compounds were characterized using 1HNMR. The spectrum of 4d revealed a 
singlet at δ 2.9 corresponding to six protons of N(CH3)2 group. The compound 7c   showed 
singlet at δ 3.3 for three protons of OCH3 group. The spectra of compound 7e showed two 
singlets at δ 3.4 broad and δ 3.8 for one and three protons of OH and OCH3 groups 
respectively. The compound 7h revealed multiplet signals in the range of δ 7.7-7.8 for Ar-H 
of p-chloro phenyl ring. The compounds 4d, 4g, 7c, 7e, 7h, and 7k showed multiplet signals 
in the range of  δ  6.52 - 7.5 for the protons of aromatic ring, doublets in the range of δ 2.5 for 
one proton of -CH-Cl group of azetidinone, singlet at δ 3.35 for two protons of CH2 group 
and a singlet  at  δ 8.5 for one NH proton. The NH2 proton was however, not detectable. 
Electron impact mass spectral analysis was carried out on two randomly selected compounds 
4e and 7f. The molecular mass of their corresponding molecular ion peaks (M+.) were found 
to be 524.90 and 541.11 respectively, which is in correlation with the synthesized molecules. 
The base peak of 4e and 7f was observed at 199.14 which representing the phenothiazine 
fragment. 
7.3 Biological evaluation 
7.3.1  Antibacterial screening 
All the titled compounds were investigated for antibacterial activity against NCIM and 
MTCC bacterial strains (four Gram positive and four Gram negative) by disc diffusion 
method to determine the zone of inhibition and broth dilution method to determine the 
minimum inhibitory concentration. 
Among the first series of compounds, 1-(3-chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-yl)-3-
(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea (4h) showed significant antibacterial activity  
against Gram negative organisms  P.aeruginosa and V.cholerae (zone of inhibition 19 mm 
and 18 mm respectively, MIC 62.5 µg/ml). This may be due  to the presence of electron 
withdrawing chloro phenyl group on ring nitrogen of azetidinone moiety, which is in 
  
correlation with reported azetidinone moiety possess antimicrobial action[95] or the  presence 
of phenothiazine could be another important reason for its antibacterial activity.[35] The 
compounds 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-
yl)ethyl)urea (4a) and 1-(3-chloro-2-oxo-4-styrylazetidin-1-yl)-3-(2-oxo-2-(10H-
phenothiazin-10-yl)ethyl)urea (4b), showed   mild activity against   all the Gram positive and 
Gram negative microbes.1-(3-chloro-2-(4-hydroxyphenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-
(10H-phenothiazin-10-yl) ethyl) urea (4i) showed comparable activity as that of standard 
ciprrofloxacin against E.coli  (zone of inhibition 18 mm, MIC 62.5 µg/ml) and this activity 
may be due to the presence of electron donating phenolic hydroxy group on the azetidinone 
nucleus [96]. 
Among the second series of compounds, 1-(3-chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl)-3-
(2-oxo-2-(10H phenothiazin-10-yl)ethyl)thiourea (7f) could be considered an effective 
antibacterial agent which showed almost equal activity compared to that of standard 
ciprofloxacin against Gram positive microbe S.aureus (zone of inhibition 20 mm, MIC 62.5 
µg/ml) which may be explained on the basis of nitro substituted aromatic ring on 
azetidinone.[64] The compounds  1-(3-chloro-2-(3-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-
oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea (7j), 1-(3-chloro-2-(3-fluorophenyl)-4-
oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl) ethyl)thiourea (7k) showed 
significant antibacterial activity against Gram negative microbe E.coli  (18 mm and 19 mm 
zone    of inhibition  respectively, MIC 62.5 µg/ml ). This may be due to the presence of 
chloro and flouro  substituted phenyl ring on azetidinone  moiety which has been reported to 
possess effective antimicrobial activity and may be due to increased lipophilicity of flouro 
substituted compounds.[98] Compounds 1-(3-chloro-2-(4-methoxyphenyl)-4-oxoazetidin-1-
yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea (7c), 1-(3-chloro-2-(4-chlorophenyl)-
4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea (7h) substituent were 
found to be equally effective against Gram positive microbes B.subtilis and S.albus (zone of 
inhibition 15 mm, MIC 62.5 µg/ml) and  the methoxy substituted aromatic moiety reported 
that it inhibits DNA Gyrase of Gram positive microbes[97]. 
7.3.2 Antifungal screening 
All the titled compounds were investigated for antifungal activity against four MTCC fungal 
strains by   disc diffusion method to determine the zone of inhibition and broth dilution 
method to determine the minimum inhibitory concentration. 
  
Among the first series of compounds, 1-(3-chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl)-3-(2-
oxo-2-(10H-phenothiazin-10-yl)ethyl)urea  (4f) was found to show excellent activity against 
C. albicans and M. purpurea (14 mm, 13 mm zone of inhibition respectively, MIC 62.5 
µg/ml). The compound is expected to be highly active due to the presence highly 
electronegative  nitro group in addition to the presence of azetidinone linked with urea 
moiety. The compounds 1-(3-chloro-2-(2-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-
(10Hphenothiazin -10-yl)ethyl)urea (4g), 1-(3-chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-
yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl) ethyl) urea (4h)  and 1-(3-chloro-2-(3-
chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea (4j) which 
showed equipotent activity against C.albicans M.purpurea and A.niger  (10 mm zone of 
inhibition respectively, MIC 62.5 µg/ml) which may be due to the ortho, para and meta 
substitution of chloro substituted phenyl group.[27] The  activity of 1-(3-chloro-2-(4-
hydroxyphenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea (4i) 
showed inhibition against        C. albicans (zone of inhibition 13 mm respectively, MIC 125 
µg/ml) may be attributed due to the presence of phenolic hydroxyl group in its structure. Also 
the compounds 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-
yl)ethyl)urea (4a) and 1-(3-chloro-2-oxo-4-styrylazetidin-1-yl)-3-(2-oxo-2-(10H phenothiazin 
-10-yl)ethyl)urea (4b) showed   mild activity against  the  organisms tested. 
Among the second series of compounds, 1-(3-chloro-2-(4-(dimethylamino)phenyl)-4-
oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea (7d) and 1-(3-chloro-2-
(4-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea(7h) 
was found to be highly active against T.rubrum, M.purpurea and  A.niger (16 mm, 14 mm,13 
mm, 12 mm zone of inhibition respectively, MIC 62.5 µg/ml). This activity may be due to the 
presence of thiouridyl linkage of azetidinone moiety. The compounds 1-(3-chloro-2-(3-
chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea (7j) 
and 1-(3-chloro-2-(3-fluorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-
yl)ethyl)thiourea (7k) were found to be active against C.albicans  and A.niger  (13 mm and 
10 mm zone of inhibition respectively, MIC 125 µg/ml). Compound (7b) 1-(3-chloro-2-oxo-
4-styrylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)thiourea showed very less 
antifungal activity against the fungal strains. 
 
 
  
7.3.3  Antitubercular screening 
 In vitro antitubercular screening of six compounds which showed significant antibacterial 
and antifungal activity were studied by   REMA  which revealed the compounds  1-(3-chloro-
2-(3-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea (4j), 
1-(3-chloro-2-(4-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl) 
ethyl)thiourea(7h) and 1-(3-chloro-2-(3-fluorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-
phenothiazin-10-yl) ethyl thiourea (7k) showed significant antimycobacterial activity at a 
concentration of 10 µg/ml. The activity may be due to  electon withdrawing group of  meta  
and para chloro substitution and highly electronegative group of meta flouro  substitution of 
phenyl ring at the fourth position of azetidinone  nucleus[57,59] and electron-withdrawing 
substituentson the phenothiazine ring and various halogen substitutions on the benzyl 
group.[20]  The bulkier group of compound (4d)  and electron withdrawing group of  
compound (4f) possessed antimycobacterial activity at a concentration of 100 µg/ml.[58] The 
electron donating group of hydroxyl phenyl substitution (7i) showed lack of 
antimycobacterial activity against  Mycobacterium tuberculosis H37Rv strain. 
7 .3.4 Antioxidant screening 
The antioxidant studies performed on 10 randomly selected samples against the standard 
ascorbic acid which revealed that 5 compounds (4d, 4g, 7g, 7h and 7k) showed appreciable 
DPPH radical scavenging activity with EC50 values of 55, 63, 57, 66, and 47 µg/ml 
respectively. 
FRAP radical scavenging method performed on 10 selected samples against the standard 
ferrous sulphate which revealed that 4 compounds (4d, 4g, 7i and 7k) showed excellent 
activity  with R2 values of 0.956, 0.957, 0.945, and 0.967 respectively. Compound (7k) 1-(3-
chloro-2-(3-fluorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethylthio 
urea showed significant DPPH and FRAP  radical scavenging activity compared to standard, 
because fluorine in a specified position of a molecule instead of hydrogen blocks an essential 
biochemical path and leads to inhibits the growth of disease.[45] 
 
 
 
  
7.3.5 Anticancer screening 
The in vitro anticancer studies were performed on 6 randomly selected compounds using 
MTT assay against HeLa cell line (NCCS). The results indicated that among the six  
compounds tested, the compounds 4f, 7d and 7k were found to have significant cytotoxic 
activity against Hela cell line and then IC50 values were found to be  18.26 µM, 6.13 µM and  
11.09 µM.  
The  bulkier group of dimethylamino aryl substituents on the thiazine nitrogen atom of 
phenothiazine (7d) possess excellent cytotoxic activity against nine types of cancer lines.[14]  
The   SAR studies of phenothiazine  reported flourine substituted phenyl ring (7k) showed  
good cytotoxic activity and also the highest log P value[98].  
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Twenty two novel 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-
10-yl)ethyl)urea and thiourea derivatives  were synthesized, characterized and evaluated for  
in vitro antibacterial, antifungal,  antioxidant and anticancer activities. 
1.Compound (7f) 1-(3-chloro-2-(4-nitrophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-
phenothiazin-10-yl)ethyl)urea showed could serve as novel template for bacterial infection 
chemotherapy. 
            
2.  Compound (7d) 1-(3-chloro-2-(4-(dimethylamino) phenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-
2-(10H-phenothiazin-10-yl) ethyl) thiourea may be potential candidate for new antifungal 
agent. 
 
3.  Compound (4i) 1-(3-chloro-2-(4-hydroxyphenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-
phenothiazin10yl)ethyl) urea and (7h) 1-(3-chloro-2-(4-chlorophenyl)-4-oxo azetidin-1-yl)-3-
(2-oxo-2-(10H-phenothiazin-10-yl)ethyl) thiourea exhibited significant antibacterial and 
antifungal properties.       
                          
8.CONCLUSION 
  
 
4.The compounds 1-(3-chloro-2-(3-chlorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H-
phenothiazin-10-yl)ethyl)urea (4j), 1-(3-chloro-2-(4-chlorophenyl)-4 oxo azetidin -1-yl)-3-(2-
oxo-2-(10H-phenothiazin-10-yl)ethyl) thiourea (7h) and 1-(3-chloro-2-(3-fluorophenyl)-4-
oxoazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10yl) ethyl thiourea (7k)  exhibited 
significant antimycobacterial activity at a concentration of 10 µg/ml. 
                                                                  
                                            
 
5.Compound (7k) 1-(3-chloro-2-(3-fluorophenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-2-(10H- 
phenothiazin-10-yl)ethylthiourea showed significant antioxidant activity with EC50 value  of 
47 µg/ml respectively. 
 
 
 
 
 
 
  
6.  Compound (7d) 1-(3-chloro-2-(4-(dimethylamino)phenyl)-4-oxoazetidin-1-yl)-3-(2-oxo-
2-(10H-phenothiazin-10-yl)ethyl)thiourea  exhibited significant  cytotoxicity was observed 
against HeLa cell line with IC50 value in the range of 6.13 µM respectively. 
 
The results obtained, encouraged us to pursue further research in the synthesis of many 
derivatives of titled compounds to perform in vivo trials in experimental animals to broaden 
their pharmacological assessment and receptor interactions. 
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ABSTRACT 
 A new series of twenty two novel 1-(3-chloro-2-oxo-4-phenylazetidin-1yl)-3-(2-oxo-2-(10H-
phenothiazin-10-yl)ethyl)urea and thiourea derivatives 4a-k, 7a-k were synthesized. The 
synthesized compounds were characterized by IR, MASS and 1H NMR spectral data and evaluated 
for in vitro anti-tubercular, anti-cancer, anti-bacterial, anti-fungal and antioxidant activity by 
REMA, MTT assay, disc diffusion method, MIC method, DPPH and FRAP method respectively.  
The compounds 4j, 7h and 7k at a concentration of 10 µg/ml, 4d and 4f at a concentration of 100 
µg/ml showed inhibition against the growth of Mycobacterium tuberculosis. The compounds 4f, 7d 
and 7k (18.26 µM, 6.13 µM and 11.09 µM) showed significant activity aganist human cervical 
cancer cell line (HELA).  All synthesized compounds showed moderate to significant anti-bacterial 
and anti-fungal activity and compounds 4d, 4g, 7i and 7k showed good antioxidant activity. The 
synthesized compound 7k showed broad spectrum of action for in vitro anti-tubercular, anti-
cancer, anti-bacterial, anti-fungal and anti-oxidant activity. 
Keywords:   Phenothiazines, 2-azetidinones, MTT Assay, REMA 
 
 
 
 
